5,6-Bis(4-hydroxyphenyl)-5-octenyl methanesulfonate (43): yield 167 (97%) of an oil; ¹H NMR (400 MHz, acetone- $d_{\rm e}$) δ 0.76 (t, 8-CH₃), 0.88 (t, 8-CH₃, styrene), 0.92 (t, 8-CH₃, (Z)-stilbene), 1.30 (quint, CH₂), 1.47 (d, CH₃), 1.54 quint, CH₂), 1.63–1.863 (m, CH₂), 1.90 (d, CH₃), 2.18 (q, 7-CH₂), 2.22 (t, 4-CH₂), 2.56 (q, 7-CH₂), (Z)-stilbene), 2.60 (t, 4-CH₂, (Z)-stilbene), 2.98 (s, SO₃CH₃), 3.01 and 3.04 (each s, SO₃CH₃), 3.33 and 3.46 (each t, benzylic H), 4.03 (t, 1-CH₂), 4.15–4.22 (several t, 1-CH₂), 5.56 (t, vinylic styrene H), 6.54–7.09 (m, Ar-H), 8.1–8.3 (br, OH); MS (160 °C) m/z 390, (78, M⁺), 294 (46), 279 (16), 265 (87), 253 (57), 239 (75), 237 (61), 223 (54), 181 (31), 171 (48); exact mass calcd for C₂₁H₂₆O₅S 390.1501, found 390.1504.

2-[[[[5,6-Bis(4-hydroxyphenyl)-5-octen-1-yl]oxy]carbonyl]amino]-2-chloroethane (44): yield 50 mg (93%) of an oil; IR (CHCl₃) 3450 (NH), 3330 (OH), 1710 cm⁻¹ (urethane C==O); ¹H NMR (90 MHz, CDCl₃, acetone- d_6/D_2O) δ 0.73 (t, 3 H, 8-CH₃), 1.11–1.55 (m, 4 H, CH₂), 2.00–2.24 (m, 4 H, CH₂), 3.33–3.66 (m, 4 H, NCH₂CH₂Cl), 3.87 (t, 2 H, 1-CH₂), 5.25 (t, 1 H, NH), 6.77–7.07 (m, 8 H, Ar-H); MS (200 °C) m/z 419 (41 5, M⁺), 417 (100, M⁺), 332 (25), 330 (74), 265 (44), 253 (59), 239 (66), 237 (74), 224 (26), 223 (20), 161 (60); exact mass calcd for C₂₃-H₂₈NO₄Cl, 417.1707, found 417.1699.

Registry No. 1, 50-28-2; 3, 56-53-1; 4, 120-44-5; 5, 6182-78-1; 6, 67566-88-5; 7, 120743-85-3; 8, 120743-41-1; 9a, 120743-42-2; 9b, 120743-72-8; E-10, 120743-43-3; Z-10, 120743-73-9; E-11, 120743-44-4; Z-11, 120743-74-0; E-12, 120743-45-5; Z-12, 120743-75-1; E-13, 120788-27-4; Z-13, 120743-76-2; E-14, 120743-46-6; Z-14, 120743-77-3; E-17, 120743-47-7; Z-17, 120743-78-4; E-18, 120743-48-8; E-19, 120743-49-9; Z-19, 120743-79-5; E-20, 120743-50-2; Z-20, 120743-80-8; E-21, 120743-51-3; Z-21, 120743-81-9; E-22, 120743-52-4; Z-22, 120743-82-0; 23, 120743-53-5; E-24, 120743-54-6; E-25, 120743-55-7; Z-25, 120743-83-1; E-26, 120771-41-7; E-27, 120743-56-8; E-28, 120743-57-9; E-29, 120743-58-0; E-30, 120771-42-8; 31, 120743-59-1; E-32, 120743-60-4; E-33, 120743-61-5; 34, 120743-62-6; E-35, 120743-63-7; E-36, 120743-64-8; Z-36, 120743-84-2; E-37, 120743-65-9; E-38, 120743-66-0; Z-38, 120771-43-9; E-39, 120743-67-1; E-40, 120743-68-2; 41-HCl, 120743-69-3; 43, 120743-70-6; 44, 120743-71-7; p-ClC₆H₄OH, 106-48-9; p-O₂NC₆H₄OH, 100-02-7; tert-butyl 4-chlorobutyrate, 3153-32-0; ethyl bromide, 74-96-4; octyl bromide, 111-83-1; 4-nitrophenol, 100-02-7; tert-butylphenol, 27178-34-3; pentachlorophenol, 87-86-5; diethanolamine, 111-42-2; daunorubicin hydrochloride, 23541-50-6; β -chloroethylammonium chloride, 870-24-6.

Hexestrol-Linked Cytotoxic Agents: Synthesis and Binding Affinity for Estrogen Receptors


Hannelore Köhle,[†] Karsten Krohn,^{*,†} and Guy Leclercq[‡]

Institut für Organische Chemie der Technischen Universität Braunschweig, Hagenring 30, D-3300 Braunschweig, Federal Republic of Germany, and Laboratoire de Cancérologie mammaire, Service de Médicine, Institut J. Bordet, 1000 Brussels, Belgium. Received August 16, 1988

With the *erythro*-hexestrol derivative 2 as the starting material, a variety of cytotoxic linked hexestrol (HEX) compounds were prepared including the HEX-N-lost derivative 36, the HEX-(chloroethyl)nitrosourea 38, the HEX-cyclophosphamide 44, and the HEX-epoxide 68. Relative binding affinity to estradiol receptors were in the magnitude of 1%, similar to that of comparable diethylstilbestrol compounds. HEX derivatives with long polyether spacers (64, 65, 70, 71) showed no significant decrease in binding affinity in contrast to derivatives with other bulky side chains.

In the preceding paper¹ we outlined the general concept of linking cytotoxic groups to synthetic estrogens. The basic idea is to increase the specificity in the treatment of hormone-dependent cancers by reducing the systemic toxicity of the drugs (compare ref 2-4). A series of diethylstilbestrol (DES) derivatives were prepared and the receptor binding affinity was measured.¹ However, the chemical investigation revealed that unsymmetrically substituted DES derivatives equilibrate in solution to a mixture of the corresponding (E)- and (Z)-stilbenes and also, to some extent, to the two isomeric styrenes. It is known that hexestrol (HEX) has comparable binding affinity as DES,^{5,6} and we now present an extensive investigation on the chemical derivatization and binding properties of HEX derivatives. The chemically stable skeleton now allowed the synthesis of isomerically pure compounds and the attachment of highly reactive cytotoxic groups.

HEX derivatives that are substituted in the aromatic ring were obtained from the parent hexestrol.⁷⁻¹¹ Sidechain derivatives can be synthesized in a number of ways such as the condensation of 4-methoxybenzaldehyde with 4-methoxybenzyl cyanide,⁴ the addition of silylketene Scheme I



acetals with allylsilanes,¹² or the Reformatzky¹³ or the McMurry reaction¹⁴⁻¹⁶ followed by hydrogenation. It is


[†]Institut für Organische Chemie der Technischen Universität Braunschweig.

[‡]Institut J. Bordet.

⁽¹⁾ Krohn, K.; Kulikowski, K.; Leclercq, G. J. Med. Chem. Preceding paper in this issue.

⁽²⁾ Leclercq, G.; Heuson, J.-C. Cancer Treat. Rep. 1978, 62, 1255.

Chart I



known that relatively high binding affinity is only maintained if both phenolic hydroxy groups of the HEX derivatives are free.^{2,3,9,17,18} In addition, larger groups neighboring the hydroxy groups decrease the binding affinity.^{7,11,19}


Chemical Synthesis

Thus, as in the preceding paper,¹ we linked the cytotoxic groups to the side chain with a spacer of varying length. The synthesis started from the readily available tertiary alcohol $1,^{20}$ which is obtained from deoxyanisoin as a 1:4

- (3) Leclercq, G.; Devleeschouwer, N.; Heusen, J. C.; Heuson, J. C. In vitro screening for cytotoxic estrogens of potential therapeutic acticity. In "Cytotoxic Estrogens in Hormone Receptive Tumors", Raus, J.; Martens, H.; Leclercq, G., Ed.; Academic Press: New York, 1980; pp 165-181.
- (4) Hamacher, H.; Mangold, C. Arch. Pharm. 1983, 316, 271.
- (5) Landvatter, S. W.; Katzenellenbogen, J. A. J. Med. Chem. 1982, 25, 1300.
- (6) Landvatter, S. W.; Katzenellenbogen, J. A. Mol. Pharmacol. 1981, 20, 43.
- (7) Hamacher, H.; Sand, J.-M. Arch. Pharm. 1981, 314, 631.
- (8) Heiman, D. F.; Senderoff, S. G.; Katzenellenbogen, J. A.; Neeley, R. J. J. Med. Chem. 1980, 23, 994.
- (9) Katzenellenbogen, J. A.; McGorrin, R. J.; Tatee, T.; Kempton, R. J.; Carlson, K. E.; Kinder, D. H. J. Med. Chem. 1981, 24, 435.
- (10) Hamacher, H. Arch. Pharm. 1978 311, 184.
- (11) Hamacher, H.; Sand, J.-M. Arch. Pharm. 1981, 314, 631.
- (12) Mohan, R.; Katzenellenbogern, J. A. J. Org. Chem. 1984, 49, 1238.
- (13) Goswami, R.; Harsy, S. G.; Heiman, D. F.; Katzenellenbogen, J. A. J. Med. Chem. 1980, 23, 1002.
- (14) Hartmann, R. W.; Schwarz, W.; Schönenberger, H. J. Med. Chem. 1983, 26, 1137.
- (15) Hartmann, R. W.; Schwarz, W.; Heindl, A.; Schönenberger, H. J. Med. Chem. 1985, 28, 1295.
- (16) Hartmann, R. W.; Kranzfelder, G.; Anger, E. v.; Schönenberger, H. J. Med. Chem. 1980, 23, 841.
- (17) Hamacher, H.; Brecht, B. Arch. Pharm. 1977, 310, 662.
- (18) Elian, I.; Ionescu, D.; Tarnauceanu, E.; Niculescu-Duvaz, I.; Leclercq, G.; Devleeschouwer, N. Eur. J. Med. Chem.-Chim. Ther. 1983, 18, 385.
- (19) Geynet, G.; Millet, C.; Truong, H.; Baulieu, E. E. Gynecol. Invest. 1972, 3, 2.
- (20) Krohn, K.; Hemme, C. Liebigs Ann. Chem. 1978, 726.

Journal of Medicinal Chemistry, 1989, Vol. 32, No. 7 1539

Scheme II



mixture of isomers.¹ The benzylic hydroxy group of 1 could be removed by hydrogenation in the presence of acid²¹ with simultaneous ester cleavage to quantitatively produce a 1:1 mixture of the erythro and three acids 2 and 4 as shown in Scheme I. The ratio of the erythro and threo acids 2 and 4 was irrespective of the isomeric ratio of the starting material 1. Fortunately, the biologically more active erythro compound crystallized and all the subsequent derivatives were prepared in isomerically pure form. The structural assignment of acids 2 and 4 were made on the corresponding alcohols 3 and 5, which were obtained by reduction with lithium aluminum hydride (LAH). Extensive 2D NMR studies (INADEQUATE and ¹³C, ¹H correlation techniques) enabled a correct assignment of all NMR signals and the structural determination could be made from the coupling constants of the nonequivalent benzylic protons.²²


In the course of the syntheses a careful choice of the protecting groups had to be made depending on the chemical stability of the attached electrophilic groups. The methoxy group of the starting material 2 could be carried through a long reaction sequence if the acidic conditions of the ether cleavage with boron tribromide could be tolerated. In other cases the *tert*-butyldimethylsilyl (TBDMS) group or the benzyl group offered advantages and sometimes a direct attachment to the free bisphenol was possible.

Alcohol 3 served as the parent compound for a number of derivatives listed in Chart I in which the hydroxy group was exchanged by a halide or a thioethanol group. Halides 6 and 8 were prepared by reaction of 3 with thionyl chloride or N-methyldicyclohexylcarbodiimidium iodide.²³ Treatment of alcohol 3 with 48% hydrogen bromide was accompanied by methyl ether cleavage to 13. Nucleophilic displacement of iodide in 8 with thioethanol afforded thioether 9. A derivative in which the halide is replaced by hydrogen was obtained by hydrogenation of a Grignard adduct similar to 1 (CO_2 -t-Bu replaced by CH_3).¹ Again, a 1:1 mixture of isomers resulted and the erythro derivative 10 crystallized. All of the arylmethyl ethers were cleanly cleaved with BBr₃ in dichloromethane at -70 °C to afford the bisphenols 11-16. The 2-hydroxyethyl octyl thioether

- (22) Kilbourn, M. R.; Arduengo, A. J.; Park, J. T.; Katzenellenbogen, J. A. Mol. Pharm. 1981, 19, 388.
- (23) Scheffold, R.; Saladin, E. Angew. Chem. 1972, 84, 158; Angew. Chem., Int. Ed. Engl. 1972, 11, 229.

⁽²¹⁾ Angerer, E. V.; Kranzfelder, G.; Taneja, A. K.; Schönenberger, H. J. Med. Chem. 1980, 23, 1347.


Scheme III



17 was available by direct iodide displacement of bisphenol 14 with mercaptoethanol. An interesting compound for binding studies, in which all the positions ortho to the phenol are blocked, was obtained on treatment of 3 with triphenylphosphine and bromine²⁴ to afford 18.

A common feature of all the compounds prepared next (Scheme II) is the nitrogen atom replacing the heteroatom in the side chain in 6-16. They were prepared via the activated 4-nitrophenyl or pentachlorophenyl esters 19 and 20 by reaction with the corresponding amines (NH_3) , NH_2CH_3 , $NH(CH_2CH_2OH)_2$, $NH_2CH_2CH_2OH$, NH₂CH₂CH₂CO₂Et) to afford amides 21-25. For the purpose of binding studies the methyl ethers were cleaved with BBr₃ to yield the corresponding bisphenols 26-29. Amides 21, 23, and 24 were reduced with LAH to amines 30-32. For the preparation of the cytotoxic N-lost compounds 36 and 37, the aryl methyl ethers of amines 31 and 32 were cleaved with BBr_3 and the resulting phenols 34 and 35 were treated with $SOCl_2$ to give chlorides 36 and 37. Nitrogen-lost compounds are potent alkylants and a number of derivatives are used in cancer treatment.²⁵ The bisalkylation derivative 36 is particularly well adapted for cross-linking DNA strands. The HEX-linked lost compound 36 has a spacer that is three carbons longer than the similar compound prepared by Hamacher and Mangold.4

Another group of potent anticancer drugs are derived from N-nitrosourea and some drugs of this kind are in clinical use (Carnustin, Lomustin).²⁵ The (2-chloroethyl)nitrosourea group does not survive BBr₃ treatment and alkaline or hydrogenating conditions are also insuitable. We therefore designed a synthesis in which an appropriately activated 2-chloroethyl-N-nitroso group is directly attached to the bisphenolic primary amine **33**. As a precursor, the known²⁶⁻²⁸ crystalline azide **39** was niChart II



trosated to the oily nitroso azide 40 (Scheme II). Coupling of 40 with amine 33 in pyridine directly provided the HEX-linked nitrosourea compound 38. Interestingly, the predominant fragmentation in the mass spectrum was the formation of an isocyanate. Isocyanate formation is also a process of biotransformation and the alkylation of amines present in the cell is believed to be responsible for the cytostatic activity.²⁵

Next, the very well known cyclophosphamide group was linked to the HEX molecule as shown in Scheme III. Cyclophosphamides (e.g. endoxane) are widely used in anticancer treatment in humans.²⁹ The in vivo activation occurs by enzymatic hydroxylation of the C-4 position, ring opening, and elimination of acrolein.³⁰ A good choice to link the HEX molecule to cyclophosphamide would be the secondary nitrogen atom which is not eliminated during the bioactivation process. However, a direct coupling of the prebuilt cyclophosphamide to an electrophilic HEX derivative such as iodide 14 was not possible. Cyclophosphamide 43 was eventually constructed by condensation of N_N -bis(2-chloroethyl)phosphoric acid amide dichloride 42 with amino alcohol 41 in pyridine (94%). Amino alcohol 41 was obtained by LAH reduction of the β -amino ester 25 to 41. The other building block 42 was prepared according to a procedure of Friedmann and Seligmann.³¹ A new chiral center was introduced with the tetracoordinated phosphorus and a mixture of diastereomers would be expected to result from the coupling. In fact, two signals could be seen in the ³¹P NMR spectrum for the phosphorus atom.

A number of functional groups which we intended to link to HEX were not compatible with the ether cleavage conditions with BBr₃. The *tert*-butyldimethylsilyl (TBDMS) group was therefore introduced by reaction of phenolic acid 51 with *tert*-butyldimethylsilyl chloride and imidazole in DMF. An intermediate silyl ester was cleaved by addition of methanol to afford bis(silyl ether) 45. Acid 45 (Chart II) was then reduced with LAH to give alcohol 46 in 86% yield. Prolonged reaction and elevated reaction temperatures lead to partial silyl ether cleavage and the reaction had to be carefully monitored by TLC. Alcohol 46 was then converted into a number of electrophilic esters by reaction with the corresponding acid chlorides in pyr-

- (28) Lam, H.-Y.; Begleiter, A.; Goldenberg, G. J. J. Med. Chem. 1979, 22, 201.
- (29) Hill, D. L. A Review of Cyclophosphamide; Thomas: Springfield, IL, 1975.
- (30) Lorent, P.; Wiessler, P. Arch. Pharm. 1985, 318, 577.
- (31) Friedman, O. .; Seligman, A. M. J. Am. Chem. Soc. 1954, 76, 655.


⁽²⁴⁾ Wiley, G. A.; Hershkowitz, R. L.; Rein, B. M.; Chung, B. C. J. Am. Chem. Soc. 1964, 86, 964.

⁽²⁵⁾ Schunack; Meyer; Haake Arzneistoffe; Vieweg: Braunschweig, 1983.

⁽²⁶⁾ Meier, A.; Stoos, F.; Marhin, D.; Buyuk, G.; Mardegger, E. Helv. Chim. Acta 1974, 57, 2622.

⁽²⁷⁾ Eisenbrand, G.; Fiebig, H. H.; Zeller, W. J. Z. Krebsforsch. Klin. Onkol. 1976, 86, 279.

Chart III



idine. The silyl ether cleavage could finally be effected by fluoride ion treatment under essentially neutral conditions to afford phenols 11 and 52-55.


As a third protecting group the base- and acid-stable benzyl ether group was introduced by converting phenolic acid 51 to perbenzylated ester 56. LAH reduction of 56 afforded alcohol 58, which was converted to iodide 59 by treatment with N-methyldicyclohexylcarbodiimidium iodide²³ (Chart III). Displacement reactions of 59 with mono-, di-, and triethylene glycol gave the corresponding alcohols 60–62. Hydrogenolysis liberated free phenols 69–71 and chlorination with thionyl chloride gave chlorides 63–65.

Finally, it was intended to introduce an epoxy function as a potent electrophilic group. Acid 51 was converted to methyl ether 57 by treatment with diazomethane. Methyl ester 57 was reduced with diisobutylaluminum hydride (DIBAH) to aldehyde 66 and subsequent Wittig reaction furnished the terminal olefin 67, which was epoxidized with m-chloroperbenzoic acid (MCPBA) to epoxide 68.

Estrogen Receptor Binding

Table I gives the relative binding affinities (RBA, $E_2 =$ 100) for selected HEX derivatives. The magnitude of the binding is comparable to that of the analogous DES derivatives published in the preceding paper.¹ Again, acidic groups like carboxylic acids (compound 51) strongly decreased the RBA. No such decrease can be seen in the amine hydrochlorides (e.g. 34, 36) which also have higher RBA as the corresponding amides (28 and 27). A similar decrease in the RBA is observed with the tetrabromo HEX derivative 18 in which the phenolic hydroxy groups are blocked by four neighboring bromo atoms. Generally, larger side chains with hydrophobic as well as hydrophilic terminating groups decrease the RBA (compare ref 5). This is demonstrated with the homologous halides in which iodide 14 has a lower RBA (0.2) than the corresponding bromide 13 (1.0) or chloride 12 (1.5) (compare ref 13). However, no such decrease occurs in the polyether compounds 63-65 and 69-71 even with very long side chains. An explanation of this remarkable effect might be found in the random coil conformation of longer hydrophobic side chains whereas the polyether spacers could assume a more linearly stretched conformation due to hydrogen bonding with water molecules. This hypothesis is supported by the much lower RBA of the corresponding thioether compounds 15 and 17 since sulfur is less able to form hydrogen bonds in aqueous solution. This might be of general im
 Table I. Estradiol Receptor Binding Affinities of HEX

 Derivatives



no.	R	RBA
51	COOH	0.1
29	CONHCH ₂ CH ₂ OH	0.1
18	$CH_2OH, R^3 = Br$	0.1
57	CO_2CH_3	0.2
28	$CONH(CH_2CH_2OH)_2$	0.2
14	CH_2I	0.2
15	CH_2SEt	0.2
27	CONHCH ₃	0.2
54	$CH_2OSO_2CH_3$	0.3
63	$CH_2OCH_2CH_2Cl$	0.3
17	$CH_2SCH_2CH_2OH$	0.4
65	$CH_2(OCH_2CH_2)_3Cl$	0.5
26	CONH ₂	0.9
34	$CH_2N(CH_2CH_2OH)_2$	0.9
16	CH ₃	1.0
38	CH ₂ NHCON(NO)CH ₂ CH ₂ Cl	1.0
37	CH ₂ NHCH ₂ CH ₂ Cl·HCl	1.0
13	CH ₂ Br	1.0
52	CH ₂ OCOCH ₃	1.0
66	CHO	1.0
67	$CH = CH_2$	1.0
68	$CH(0)CH_2$	1.0
69	CH ₂ OCH ₂ CH ₂ OH	1.0
70	CH ₂ (OCH ₂ CH ₂) ₂ OH	1.0
71	CH ₂ (OCH ₂ CH ₂) ₃ OH	1.0
64	$CH_2(OCH_2CH_2)_2Cl$	1.0
44	CH ₂ -cyclophosphamide	1.0
12	CH_2Cl	1.5
11	CH₂OH	1.5
33	CH_2NH_2	2.0
36	$CH_2N[(CH_2)_2Cl]_2\cdot HCl$	2.5

portance if biologically active molecules are attached to spacers. Data on the potential therapeutic value of such compounds are too few to be reported here. However, it should be stressed that preliminary in vitro studies on MCF-7 breast cancer cells (for experimental protocol, see ref 3) revealed no major cytotoxicity for compounds 34 and 36. Since mustime is extremely toxic in this model,³ it appears that the grafting of the alkylating group largely reduces its efficiency. However, the relatively high RBA of the N-lost compound 33, the N-nitrosourea 38, and the cyclophosphamide 44 merits further in vivo investigation in the treatment of estrogen-dependent tumors. It should be noted that irreversible receptor binding of some of the strongly alkylating derivatives tested is possible.³² The present data on HEX and DES¹ show that the grafting of a cytotoxic moiety on diphenolic estrogens reduces their binding affinity for the receptor even in the presence of a spacer. However, this observation should not reject the approach since the reduction is not as strong as usually found with a direct lincage. The synthesis of spacer-containing estrogenic platinum complexes, reported at the time of submission of our studies,³³ totally supports this impression.

Experimental Section

For general methods and measurement of binding affinities, see ref 1 and 34. The following range of bands in the IR and

⁽³²⁾ Zablocki, J. A.; Katzenellenbogen, J. A.; Carlson, K. E.; Norman, M. J. J. Med. Chem. 1987, 30, 829.

⁽³³⁾ Knebel, N.; von Angerer, E. J. Med. Chem. 1988, 31, 1675.

UV spectra were found for HEX ethers: UV λ_{max} (log ϵ) 210–212 (4.1), 226–228 (4.3), 272–277 (3.5), 280–285 nm (3.4); IR 3020–2830, 1610–1615, 1580–1585, 1509–1510, 1255–1255, 1175–1180, 1040–1035, 812–835 cm⁻¹. The corresponding HEX derivatives had the following values: UV λ_{max} (log ϵ) 208–216 (4.1), 227–228 (4.3), 278–279 (3.6), 283–285 nm (3.5); IR 3260–3240, 3020–2850, 1610–1612, 1600, 1510–1513, 1450–1457, 1377–1385, 1238–1264, 1113–1105, 1013, 830–835 cm⁻¹.

(5S*,6R*)-5,6-Bis(4-methoxyphenyl)-1-octanoic Acid (2) and $(5S^{*}, 6S^{*})$ -5,6-Bis(4-methoxyphenyl)-1-octanoic Acid (4). A solution of 8.00 g of alcohol 1 in 100 mL of acetic acid was treated with 100 mg of Pd/C and 5 drops of perchloric acid. Hydrogenation was effected at 3 bar. The catalyst was filtered off, the filtrate was neutralized with NaHCO₃ solution, and the product was extracted with dichloromethane. The solvent was removed under reduced pressure and the residue (6.65 g, 100%) cyrstallized from 5 mL of dichloromethane to afford 3.00 g (45.5% of the pure erythro compound 2. Data for 2: ¹H NMR (400 MHz, $CDCl_3$) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 1.20–1.46 (m, 6 H, 3, 4, 7-H), 2.09 (m, 2 H, 2-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.58 (m, 1 H, 5-H), 3.79 and 3.81 (each s, 3 H, 2 OCH₃), 6.86 (d, 2 H, J = 8.5 Hz, 4 H, ArH ortho to OCH₃), 7.06 (d, 2 H, J = 8.5Hz, 4 H, ArH); IR (KBr) 1708 cm⁻¹ (CO); MS (160 °C) m/z 207 (62), 189 (5), 171 (19), 161 (8), 149 (100).

Data for 4: ¹H NMR (400 MHz, CDCl₃) δ 0.73 (t, J = 7.5 Hz, 3 H, 8-H), 1.14–1.87 (m, 6 H, 3, 4, 7-H), 2.17–2.31 (m, 2 H, 2-H), 2.64 (ddd, J = 4.5, 6.5, 10 Hz, 1 H, 6-H), 2.77 (ddd, J = 4.5, 6.5, 10 Hz, 1 H, 5-H), 3.74, 3.75 (s, 3 H, OCH₃), 6.69 (d, J = 8.5 Hz, 4 H, ArH), 6.74 (d, J = 8.5 Hz, 4 H, ArH); IR (CCl₄) 1710 cm⁻¹ (CO).

 $(5S^{*}, 6R^{*})$ -erythro-5, 6-Bis(4-methoxyphenyl)-1-octanol (3). A suspension of 0.08 g (2.1 mmol) of lithium aluminum hydride (LAH) in 10 mL of absolute THF at 0 °C was treated with a solution of 1.00 g (2.8 mmol) of acid 2. After stirring for 4 h at room temperature, the mixture was hydrolyzed with 30 mL of 1 N HCl and the product was extracted with diethyl ether. The ethereal solution was washed with a NaHCO₃ solution and water, dried with Na_2SO_4 , filtered, and evaporated, and the residue was crystallized from dichloromethane/petroleum ether to afford 0.89 g (93%) of 3: mp 59-61 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 8-H), 0.85-1.75 (m, 8 H, 2-, 3-, 4-, 7-H), 2.46(dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.58 (dt, J = 4.5, 10, 10 Hz,1 H, 5-H), 3.41 (m, 2 H, 1-H), 3.81 (s, 6 H, 2 OCH₃), 6.85 (2 d, J = 8.5 Hz, 4 H, ArH), 7.07 (d, 2, J = 8.5 Hz, 4 H, ArH); ¹³C NMR (75.5 MHz, CDCl₃) δ 12.18 (q, C-8), 23.63 (t, C-3), 27.34 (t, C-7), 32.55 (t, C-2), 34.17 (t, C-4), 51.46 (d, C-5), 53.67 (d, C-6), 55.18 (q, 2 OCH₃), 62.78 (t, C-1), 113.65 (d, C-11, 13, 17, 19), 129.12 (d, C-10, 14, 16, 20), 136.46 (s, C-9, C-15), 157.87 (s, C-12, C-18).

 $(5S^*, 6S^*)$ -threo-5,6-Bis(4-methoxyphenyl)-1-octanol (5). One gram (2.8 mmol) of threo acid 4 was reduced with 0.08 g (2.1 mmol) of LAH to afford 0.86 g (89%) of oily alcohol 5: ¹H NMR (400 MHz, CDCl₃) δ 0.74 (t, J = 7 Hz, 3 H, 8-H), 1.08–1.21 (m, 2 H, 3-H), 1.40–1.84 (m, 6 H, 2-, 4-, 7-H), 1.86 (s, 1 H, OH), 2.63 (ddd, J = 4.5, 6.5, 10 Hz, 1 H, 6-H), 2.75 (ddd, J = 4.5, 6.5, 100 Hz, 1 H, 6-H), 2.75 (ddd, J = 4.5, 6.5, 100 Hz, 1 H, 5-H), 3.51 (dt, 2 H, 1-H), 3.72 (s, 6 H, 2 OCH₃), 6.69 (2 d, J = 8.5 Hz, 4 H, ArH), 6.74 (d, J = 8.5 Hz, 4 H, ArH); ¹³C NMR (100.6 MHz, CDCl₃) δ 12.32 (q, C-8), 23.91 (t, C-3), 26.06 (t, C-7), 32.79 (t, C-2), 33.10 (t, C-4), 50.40 (d, C-5), 52.62 (d, C-6), 55.03 (q, 2 OCH₃), 62.72 (t, C-1), 112.90 (d, C-11, 13, 17, 19), 129.88 (d, C-10, 14, 16, 20), 134.85 (s, C-9, C-15), 157.62 (s, C-12, C-18).

erythro-5,6-Bis(4-methoxyphenyl)-1-octyl Chloride (6). A solution of 443 mg (1.3 mmol) of alcohol 3 in 10 mL of CCl₄ was treated with 1 mL of DMF and 0.15 mL (1.9 mmol) of thionyl chloride and stirred for 2 h. The mixture was then poured into water, the organic solvent was evaporated under reduced pressure, and the residue was crystallized from ethyl acetate to yield 421 mg (91%) of 6: mp 65 °C; ¹H NMR (90 MHz, CDCl₃) δ 0.51 (t, J = 7 Hz, 3 H, 8-H), 0.78-1.71 (m, 8 H, 2, 3, 4, 7-H), 2.39-2.67 (m, 2 H, 5, 6-H), 3.25 (t, 2 H, 1-H), 3.79 (s, 6 H, OCH₃), 6.82 (d, J = 8 Hz, 4 H, ArH), 7.06 (d, J = 8 Hz, 4 H, ArH).

erythro-5,6-Bis(4-methoxyphenyl)-1-octyl Iodide (8). A solution of 0.30 g (0.88 mmol) of alcohol 3 and 1.02 g (1.84 mmol)

of N-methyl-N,N'-dicyclohexylcarbodiimidium iodide²³ in 15 mL of absolute THF was stirred overnight at room temperature. The solution was diluted with 50 mL of diethyl ether, washed with water and a solution of sodium thiosulfate, dried with Na₂SO₄, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (CH₂Cl₂) and crystallized from ethyl acetate/petroleum ether to give 0.38 g (91%) of iodide 8: mp 86 °C; ¹H NMR (90 MHz, CDCl₃) δ 0.53 (t, J = 7.5 Hz, 3 H, 8-H), 0.89–1.9 (m, 8 H, 2, 3, 4, 7-H), 2.40–2.64 (m, 2 H, 5, 6-H), 2.91 (t, J = 7 Hz, 2 H, 1-H), 3.80 (s, 6 H, OCH₃), 6.82 (d, J = 8 Hz, 4 H, ArH), 7.05 (d, J = 8 Hz, 4 H, ArH).

erythro-5,6-Bis(4-methoxyphenyl)octyl Ethyl Thioether (9). A solution of 0.2 mL of ethanethiol in 3.0 mL of dry THF was treated with 10 mg of NaH. After 0.5 h 100 mg (0.2 mmol) of iodide 8 was added and stirring was continued for 8 h at 20 °C. The mixture was neutralized with 2 N HCl and extracted with diethyl ether. The dried solution was evaporated and the residue crystallized from diethyl ether to afford 81 mg (98%) of thioether 9: mp 46 °C; ¹H NMR (90 MHz, CDCl₃) δ 0.40–0.71 (m, 6 H, 8, 2'-H), 0.96–1.60 (m, 8 H, 2-, 3-, 4-, 7-H), 2.16–2.71 (m, 6 H, 1-, 1'-, 5-, 6-H), 3.78 (s, 6 H, OCH₃), 6.84 (d, J = 8 Hz, 4 H, ArH), 7.07 (d, J = 8 Hz, 4 H, ArH).

erythro-3,4-Bis(4-methoxyphenyl)octane (10). A solution of 1.22 g (3.76 mmol) of 3,4-bis(4-methoxyphenyl)-3-octene¹ in 30 mL of ethanol/acetic acid (2.1) was hydrogenated as described for 2 to afford 1.16 g (95%) of oily 10 as a 1:1 mixture of the erythro and three compounds. The erythro derivative 10 crystallized from ethyl acetate (0.49 g, 40%): mp 74 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 1-H), 0.67 (t, J = 7.5 Hz, 3 H, 8-H), 0.84–1.44 (m, 8 H, alkyl-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 3-H), 2.56 (dt, J = 4.0, 10, 10 Hz, 1 H, 4-H), 3.81 (s, 6 H, OCH₃), 6.83 (d, J = 8.5 Hz, 4 H, ArH), 7.07 (2 d, J = 8.5 Hz, 4 H, ArH); MS (70 °C m/z 326 (2, M⁺), 177 (86), 149 (88), 134 (26), 121 (100), 91 (35).

erythro-5,6-Bis(4-hydroxyphenyl)-1-octanol (11). A solution of 500 mg (1.5 mmol) of alcohol 3 in 20 mL of dry CH_2Cl_2 was treated at -50 °C with 0.2 mL of BBr₃ (2.24 mmol). The solution was stirred for 3.5 h at room temperature, poured onto 100 mL of ice-water, and extracted with diethyl ether. The etheral solutions were dried (Na₂SO₄), evaporated, and crystallized from petroleum ether/ethyl acetate to afford 4.16 g (91%) of oily phenol 11: ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 8-H), 0.80–1.47 (m, 8 H, 2-, 3-, 4-, 7-H), 2.43 (m, 1 H, 6-H), 2.54 (m, 1 H, 5-H), 3.43 (m, 2 H, 1-H), 4.67 (s, 2 H, ArOH), 6.78 (d, 2, J = 8.5 Hz, 4 H, ArH), 7.00 (d, 2, J = 8.5 Hz, 4 H, ArH); MS (150 °C) m/z 314 (0.7, M⁺), 212 (5), 199 (3), 179 (55), 161 (83), 135 (88). Anal. (C₂₀H₂₆O₃) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Chloride (12). Methyl ether 6 (156 mg (0.4 mmol) was cleaved with 0.15 mL of boron tribromide as described for 11 to afford 100 mg (70%) of phenol 12: mp 166 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7.5 Hz, 3 H, 8-H), 1.00–1.66 (m, 8 H, 2-, 3-, 4-, 7-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.56 (dt, J = 4.5 Hz, 10, 10 Hz, 1 H, 5-H), 3.30 (m, 2 H, 1-H), 4.60 (s, 2 H, ArOH), 6.79 (d, J = 8.5 Hz, 4 H, ArH); MS (150 °C) m/z 332 (M⁺, Cl = 35), 212, 197, 181, 161, 147, 135 (100), 120. Anal. (C₂₀H₂₅O₂Cl) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Bromide (13). A solution of 30 mg (0.09 mmol) of alcohol 3 in 10 mL of 48% HBr and 5 mL of acetic acid was refluxed for 2 h. The reaction mixture was diluted with 100 mL of water and extracted with diethyl ether. The organic phase was washed with water and NaHCO₃ solution, dried with Na₂SO₄, and evaporated at reduced pressure. The product was purified by preparative TLC (silical gel, $CH_2Cl_2/2\%$ MeOH) and crystallized from dichloromethane to yield 19 mg (57%) of bromide 13: mp 160–161 °C; ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3) \delta 0.54 \text{ (t, } J = 7 \text{ Hz}, 3 \text{ H}, 8\text{-H}), 0.98\text{-}1.75 \text{ (m,})$ 8 H, 2-, 3-, 4-, 7-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.55 (dt, J = 5.0, 10, 10 Hz, 1 H, 5-H), 3.16 (m, 2 H, 1-H), 4.65 (br s, 10, 10 Hz, 1 H, 5-H)2 H, ArOH), 6.80 (d, J = 8.5 Hz, 4 H, ArH), 7.01 (2 d, J = 8.5Hz, 4 H, ArH); MS (120 °C) m/z 376/378 (M⁺), 243 (63), 241 (63), 161 (43), 135 (97), 120 (65), 107 (100), 91 (45); exact mass calcd for C₂₀H₂₅O₂⁷⁹Br 376.1038, found 376.1013.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Iodide (14). Fifty milligrams (0.11 mmol) of methyl ether 8 was cleaved with 1 mL of 1 M BBr₃ solution in CH₂Cl₂ to yield 36 mg (79%): mp 153

⁽³⁴⁾ Leclercq, G.; Deboel, M. C.; Heuson, J. C. Int. J. Cancer 1976, 18, 750.

°C; ¹H NMR (300 MHz, CDCl₃) δ 0.53 (t, J = 7.5, 3 H, 8-H), 1.02 (m, 2 H, 3-H), 1.18–1.42 (m, 6 H, 4-, 7-H), 2.43 (dt, 1 H, 6-H), 2.53 (dt, 1 H, 5-H), 2.95 (m, 2 H, 1-H), 4.61 (s, 2 H, ArOH), 6.78 (d, J = 8.5 Hz, 4 H, ArH), 7.01 (2 d, J = 8.5 Hz, 4 H, ArH); MS (110 °C) m/z 424 (0.2, M⁺), 289 (17), 161 (4), 135 (100), 107 (80); exact mass calcd for C₂₀H₂₅O₂J 424.0898, found 424.0897.

erythro-5,6-Bis(4-hydroxyphenyl)octyl Ethyl Thioether (15). Fifty milligrams (0.13 mmol) of methyl ether 9 was cleaved with 0.1 mL of a 1 M solution of BBr₃ as described for 11 to afford 36 mg (77%) of bisphenol 15: mp 117 °C (diethyl ether); ¹H NMR (300 MHz, CDCl₃) δ 0.54 (t, J = 7.5 Hz, 3 H, 8-H), 1.0 (m, 2 H, 3-H), 1.17 (t, J = 7 Hz, 3 H, 2'-H), 1.23–1.43 (m, 6 H, 2-, 4-, 7-H), 2.15–2.32 (m, 2 H, 1-H), 2.41 (q, J = 7 Hz, 2 H, 1'-H), 2.41 (m, 1 H, 6-H), 2.55 (dt, 1 H, 5-H), 4.65 (s, 2 H, ArOH), 6.78 (d, J =8.5 Hz, 4 H), 7.0 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3400 (OH), 3020–2860 (CH), 1610, 1600, 1510 (Ar), 1450, 1240, 1175, 830 cm⁻¹; UV λ_{max} (log ϵ) 217 sh (4.11), 228 (4.29), 279 (3.54), 285 nm (3.46); MS (100 °C) m/z 223 (100, M⁺), 161 (64), 135 (57), 120 (34), 107 (79), 91 (24), 75 (44), 67 (21), 55 (23), 41 (30); exact mass calcd for C₁₃H₁₉OS 223.1156, found 223.1156.

erythro-3,4-Bis(4-hydroxyphenyl)octane (16). Four hundred milligrams (1.23 mmol) of methyl ether was cleaved with 0.15 mL of BBr₃ as described for 11 to afford 331 mg (89%) of bisphenol 16: mp 180–182 °C; ¹H NMR (250 MHz, CDCl₃) δ 0.53 (t, 3 H, 1-H), 0.68 (t, 3 H, 8-H), 0.81–1.48 (m, 8 H, 2-, 5-, 6-, 7-H), 2.44 (dt, 1 H, 3-H), 2.56 (dt, 1 H, 4-H), 4.58 (br s, 2 H, ArOH), 6.78 (d, 4 H, ArH), 7.00 (2 d, 4 H, ArH); MS (130 °C) m/z 298 (M⁺), 212, 199, 181, 163, 135, 120, 107 (100). Anal. (C₂₀H₂₆O₂) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)octyl 2-Hydroxyethyl Thioether (17). Iodide 14 (50 mg, 0.12 mmol) was converted to the thioether as described for 9 with 16 mg (0.39 mmol) of NaH and 0.1 mL (1.43 mmol) of 2-mercaptoethanol to yield 36 mg (81%) of 17: mp 127–128 °C; ¹H NMR (300 MHz, acetone- d_6) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 1.02 (m, 2 H, 3-H), 1.22–1.40 (m, 6 H, 2-, 4-, 7-H), 2.29 (m, 2 H, 1-H), 2.47 (dt, 1 H, 6-H), 2.51 (t, 2 H, RSCH₂CH₂O), 2.59 (m, 1 H, 5-H), 3.60 (m, 2 H, CH₂O), 6.80 (2 d, J = 8.5 Hz, ArH), 7.06 (2 d, J = 8.5 Hz, ArH), 8.08 (s, 2 H, ArOH); MS (240 °C) m/z 299, 271, 265, 255, 239, 161, 135; exact mass calcd for C₁₃H₁₉O₂S 239.1106, found 239.1103.

erythro -5,6-Bis (3,5-dibromo-4-hydroxyphenyl)-1-octanol (18). A solution of 50 mg (0.15 mmol) of alcohol 3 and 41 mg (0.15 mmol) of triphenylphosphine in 3 mL of absolute DMF was treated under nitrogen with a diluted DMF solution of bromine until the color of bromine persisted. Usual workup afforded the TLC separation 41 mg (44%) of oily tetrabromide 18: ¹H NMR (400 MHz, CDCl₃) δ 0.59 (t, J = 7 Hz, 3 H, 8-H), 0.87–1.72 (m, 8 H, 2-, 3-, 4-, 7-H), 2.32 (dt, J = 3.5, 10, 10 Hz, 1 H, 5-H), 3.48 (m, 2 H, 1-H), 5.85 (br s, 2 H, ArOH), 7.20, 7.21 (s, 2 H, ArH); MS (250 °C) m/z 630 (M⁺), 528, 515, 460, 448, 381, 368, 337, 319, 293, 265, 238, 212, 131; exact mass calcd for C₂₀H₂₂O₃⁷⁹Br₂⁸¹Br₂ 629.8265, found 629.8245.

erythro-Pentachlorophenyl 5,6-Bis(4-methoxyphenyl)octanoate (19). A solution of 1.00 g (2.8 mmol) of acid 2, 752 mg (3.6 mmol) of dicyclohexyl carbodiimide (DCCI), and 0.97 g (3.6 mmol) of pentachlorophenol in 20 mL of absolute THF was stirred overnight. The solution was diluted with diethyl ether, washed with NaHCO₃ solution, dried with Na₂SO₄, and evaporated. The dicyclohexylurea was filtered off, the filtrate was evaporated to dryness, and the residue was crystallized from ethyl acetate to yield 1.53 g (90%) of ester 19: mp 148 °C; ¹H NMR (90 MHz, CDCl₃) δ 1.11–1.56 (m, 6 H, 3-, 4-, 7-H), 2.33–2.69 (m, 4 H, 2-, 5-, 6-H), 3.08 (s, 6 H, 2 OCH₃), 6.75–7.13 (m, 8 H, ArH); IR (KBr) 1775 cm⁻¹ (CO).

p-Nitrophenyl *erythro*-5,6-Bis(4-methoxyphenyl)octanoate (20). The activated 4-nitrophenyl ester 20 was prepared from 1.00 g (2.8 mmol) of acid 2, 0.51 g (3.6 mmol) of *p*-nitrophenol, and 0.75 g (3.6 mmol) of DCCI as described for 19 to afford 20 quantitatively: ¹H NMR (90 MHz, CDCl₃) δ 0.53 (t, 3 H, 8-H), 1.18-2.10 (m, 6 H, 3-, 4-, 7-H), 2.24-2.71 (m, 4 H, 2-, 5-, 6-H), 3.76 (s, 6 H, OCH₃), 6.76-7.22 (m, 10 H, ArH), 8.14 (d, 2 H, ArH); IR (KBr) 1760 cm⁻¹ (CO).

erythro-5,6-Bis(4-methoxyphenyl)octanamide (21). A stream of dry ammonia was bubbled through a solution of 1.34 g (2.8 mmol) of p-nitrophenyl ester 20 in 20 mL of dichloromethane for 0.5 h and the solution was stirred for 2 h at 20 °C.

The solution was washed with NaHCO₃ solution and water, dried with Na₂SO₄, and evaporated. The residue crystallized from diethyl ether to yield 0.82 g (82%) of amide **21**: mp 139 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 8-H), 1.01–1.75 (m, 6 H, 3-, 4-, 7-H), 1.85–2.07 (m, 2 H, 2-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.57 (ddd, 1 H, 5-H), 3.81 (s, 6 H, OCH₃), 5.13 (br s, 2 H, CONH₂), 6.86 (d, J = 8.5 Hz, 4 H, ArH), 7.04 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3420–3170 (NH), 1705 cm⁻¹ (CO). Anal. (C₂₂H₂₉O₃N) C, H.

erythro-5,6-Bis(4-methoxyphenyl)-N-methyloctanamide (22). A solution of 150 mg (0.31 mmol) of ester 20 in 5 mL of THF was treated with 32 mg (0.47 mmol) of methylamine hydrochloride and 2 mL of pyridine and stirred for 4 h. After usual workup 111 mg (97%) of methylamide 22 was obtained by crystallization from diethyl ether/petroleum ether: mp 122-123 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7.5 Hz, 3 H, 8-H), 1.17-1.43 (m, 6 H, 3-, 4-, 7-H), 1.82-2.02 (m, 2 H, 2-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.58 (ddd, 1 H, 5-H), 2.64, 2.68 (s, 3 H, NHCH₃), 3.82 (s, 6 H, 2 OCH₃), 6.86 (d, J = 8.5 Hz, 4 H, ArH), 7.07 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3320 (NH), 1650 cm⁻¹.

erythro-5,6-Bis(4-methoxyphenyl)-N,N-bis(2-hydroxyethyl)octanamide (23). A solution of 0.89 g (1.5 mmol) of pentachlorophenyl ester 19 in 20 mL of absolute THF was treated with 1 mL of diethanolamine and the mixture stirred overnight. After usual workup the product was purified by preparative TLC (SiO₂, CH₂Cl₂/4% MeOH) to afford 0.65 g (98%) of oily amide 23: ¹H NMR (400 MHz, CDCl₃) δ 0.51 (t, J = 7.5 Hz, 1 H, 8-H), 1.20–1.43 (m, 6 H, 3-, 4-, 7-H), 2.0–2.20 (m, 2 H, 2-H), 2.46 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.57 (ddd, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.27 (t, J = 5 Hz, 2 H, NCH₂), 3.42 (m, 2 H, NCH₂), 3.63 (t, J = 5 Hz, 2 H, CH₂O), 3.72 (t, J = 5 Hz, 2 H, CH₂O), 3.80, 3.82 (s, 3 H, OCH₃), 6.83 (d, 2, J = 8.5 Hz, 4 H, ArH), 7.05 (d, 2, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3360 (OH), 1620 (CO). Anal. (C₂₆H₃₇O₅N) C, H.

erythro-5,6-Bis(4-methoxyphenyl)-N-(2-hydroxyethyl)octanamide (24). A solution of 440 mg (0.73 mmol) of activated ester 19 was treated with 2 mL of ethanolamine in absolute THF as described for 23 to afford 225 mg (77%) of amide 24: mp 128 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 1.17-1.42 (m, 6 H, 3-, 4-, 7-H), 2.94 (m, 2 H, 2-H), 2.45 (dt, 1 H, 6-H), 2.54 (m, 1 H, 5-H), 3.26 (m, 2 H, NHCH₂), 3.58 (t, J = 5 Hz, 2 H, CH₂O), 3.81 (s, 6 H, OCH₃), 5.60 (br s, 1 H, NH), 6.85 (d, 2, J = 8.5 Hz, 4 H, ArH), 7.07 (d, 2, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3320-3100 (OH, NH), 1640, 1565 cm⁻¹ (CO).

erythro-5,6-Bis(4-methoxyphenyl)-N-(3-ethoxy-3-oxopropyl)octanamide (25). A solution of 2.50 g (5.2 mmol) of activated ester 20 in 20 mL of dry THF/triethylamine was treated under nitrogen with 1.29 g (8.4 mmol) of β -alanine ethyl ester hydrochloride. After stirring for 24 h at room temperature, the mixture was diluted with diethyl ether, washed with NaHCO₃ solution, water, and diluted hydrochloric acid, and dried with Na₂SO₄. The solvent was evaporated under reduced pressure and the residue purified by TLC to afford 1.51 g (63%) of amide 25: mp 72 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 1.19–1.42 (m, 6 H, 3-, 4-, 7-H), 1.25 (t, J = 7 Hz, 3 H, $CO_2CH_2CH_3$), 1.90 (m, 2 H, CH_2CONHR), 2.41 (t, J = 6 Hz, 2 H, CH₂COOR), 2.45 (m, 1 H, 6-H), 2.56 (m, 1 H, 5-H), 3.38 (dt, 2 H, $CONHCH_2R$), 3.81 (s, 6 H, OCH_3), 4.11 (q, J = Hz, 2 H, $CO_2CH_2CH_3$), 5.80 (br t, 1 H, NH), 6.86 (d, J = 8.5 Hz, 4 H, ArH), 7.06 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3330 (NH), 1730 (CO_2Et) , 1645 cm⁻¹ (CONHR).

erythro-5,6-Bis(4-hydroxyphenyl)octanamide (26). A solution of 75 mg (0.21 mmol) of methyl ether 21 was cleaved with 0.2 mL of a 1 M solution of BBr₃ in dichloromethane to afford 68 mg (98%) of 26: mp 177-179 °C; ¹H NMR (400 MHz, acetone- d_6) δ 0.50 (t, J = 7.5 Hz, 3 H, 8-H), 1.18-1.45 (m, 6 H, 3-, 4-, 7-H), 2.00-2.26 (m, 2 H, 2-H), 2.50 (ddd, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.67 (ddd, 1 H, 5-H), 6.80 (d, 2, J = 8.5 Hz, 4 H, ArH), 7.07 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3480-3150 (OH, NH), 1670, 1650 cm⁻¹ (CONH₂); MS (180 °C) m/z 327 (M⁺), 192 (100), 175 (29), 135 (61); exact mass calcd for C₂₀H₂₅O₃N 327.1834, found 327.1834.

erythro-5,6-Bis(4-hydroxyphenyl)-N-methyloctanamide (27). A solution of 80 mg (0.22 mmol) of amide 22 in 5 mL of CH₂Cl₂ was treated with 0.2 mL of a 1 M solution of BBr₃ to afford 61 mg (82%) of bisphenol 27: mp 152 °C; ¹H NMR (400 MHz, acetone- d_6) δ 0.50 (t, J = 7.5 Hz, 3 H, 8-H), 1.22–1.40 (m, 6 H, 3-, 4-, 7-H), 1.82–1.96 (m, 2 H, 2-H), 2.46 (dt, 1 H, 6-H), 2.55, 2.56 (s, 3 H, NCH₃), 2.62 (m, 1 H, 5-H), 6.71 (br s, 1 N, NH), 6.79 (d, J = 8.5 Hz, 4 H, ArH), 7.04 (2 d, J = 8.5 Hz, 4 H, ArH), 8.11, 8.12 (each s, each 1 H, OH); IR (KBr) 3500–3100 (OH, NH), 1645 cm⁻¹ (CONH); MS (210 °C) m/z 342 (100, MH⁺), 206 (88), 185 (27), 150 (25); exact mass calcd for C₂₁H₂₈O₃N 342.2060, found 342.2069.

erythro-5,6-Bis(4-hydroxyphenyl)-N,N-bis(2-hydroxyethyl)octanamide (28). Methyl ether 23 (100 mg, 0.23 mmol) was cleaved with 0.1 mL of a 1 M BBr₃ solution in dichloromethane to afford after TLC on silica gel (CH₂Cl₂/10% MeOH) 71 mg (76%) of phenol 28: ¹H NMR (250 MHz, acetone- d_6) δ 0.51 (t, J = 7.5 Hz, 8-H), 1.11–1.45 (m, 6 H, 2-, 3-, 7-H), 2.06–2.33 (m, 2 H, 2-H), 2.46 (dt, 1 H, 6-H), 2.63 (m, 1 H, 5-H), 3.00 (s, 4 H, OH), 3.37 (m, 4 H, NCH₂), 3.58 (m, 4 H, CH₂OH), 6.80 (d, J =8.5 Hz, 4 H, ArH), 7.06 (d, 2, J = 8.5 Hz, 4 H, ArH); IR (CH₃CN) 3560–3360 (OH), 1640 cm⁻¹ (CO); MS (200 °C) m/z 280 (92), 262 (52), 193 (43), 176 (58); exact mass calcd for C₁₅H₂₂NO₄ 280.1448, found 280.1470.

erythro-5,6-Bis(4-hydroxyphenyl)-N-(2-hydroxyethyl)-octanamide (29). Seventy-two milligrams (0.18 mmol) of methyl ether 24 were cleaved with 0.1 mL of a 1 M solution of BBr₃ in CH₂Cl₂ to afford after TLC (CH₂Cl₂/10% MeOH) and crystallization from ethyl acetate/petroleum ether 48 mg (72%) of 29: mp 106 °C; ¹H NMR (300 MHz, acetone- d_6) δ 0.48 (t, J = 7.5 Hz, 3 H, 8-H), 1.05–1.42 (m, 6 H, 3-, 4-, 7-H), 1.84–1.94 (m, 2 H, 2-H), 2.42 (dt, 1 H, 6-H), 2.60 (ddd, 1 H, 5-H), 3.06 (br s, OH), 3.13 (m, 2 H, NHCH₂), 3.44 (t, J = 5.5 Hz, 2 H, CH₂OH), 6.76 (d, J = 8.5 Hz, 4 H, ArH), 7.00 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 3500–3200 (OH, NH), 1630 cm⁻¹ (CO); MS (220 °C) m/z 372 (0.04, MH⁺), 353 (0.4), 236 (100), 218 (71); exact mass calcd for C₂₂-H₃₀NO₄ 372.2175, found 372.2164.

erythro-5,6-Bis(4-methoxyphenyl)-1-octylamine (30). Two grams (5.6 mmol) of amide 21 was reduced with 0.25 g (6.7 mmol) of LAH as described for 31 to yield after TLC ($CH_2Cl_2/10\%$ MeOH) purification 1.80 g (94%) of an amorphous solid that was directly transformed to bisphenol 33: IR (KBr) 3320 cm⁻¹ (NH).

erythro-5,6-Bis(4-methoxyphenyl)-N,N-bis(2-hydroxyethyl)-1-octylamine (31). A suspension of 25 mg (0.66 mmol) of LAH in 30 mL of absolute THF was treated with a solution of 550 mg (1.24 mmol) of amide 23 in 10 mL of THF and the mixture stirred for 5 h at room temperature. A diluted solution of ammonia was added and the precipitate was filtered off and extracted with diethyl ether. The filtrate was extracted with diethyl ether, and the combined organic phases were dried, evaporated, and purified by TLC (CH₂Cl₂/10% MeOH) to afford 260 mg (49%) of oily amine 31: ¹H NMR (90 MHz, CDCl₃) δ 0.53 (t, 3 H, 8-H), 0.89-1.51 (m, 8 H, 2-, 3-, 4-, 7-H), 1.58-1.71 (m, 2 H, 1-H), 230 (m, 2 H, 5-, 6-H), 2.53 (t, 4 H, NCH₂), 3.49 (t, 4 H, CH₂OH), 3.82 (s, 6 H, OCH₃), 3.97 (s, 2 H, OH), 6.83 (d, 4 H, ArH), 7.07 (d, 4 H, ArH).

erythro-5,6-Bis(4-methoxyphenyl)-N-(2-hydroxyethyl)-1-octylamine (32). A solution of 150 mg (0.38 mmol) of amide 24 was reduced with 11 mg (0.29 mmol) of LAH as described for 31 to afford 67 mg (46%) of oily amine 32: ¹H NMR (90 MHz, CDCl₃) δ 0.53 (t, 3 H, 8-H), 0.82–1.44 (m, 8 H, 2-, 3-, 4-, 7-H), 1.58–1.77 (m, 2 H, 1-H), 2.29–2.73 (m, 2 H, 5-, 6-H), 3.47–3.73 (m, 4 H, NHCH₂CH₂O), 3.63 (s, 1 H, OH), 4.13 (s, 1 H, NH), 3.85 (s, 6 H, OCH₃), 6.84 (d, 4 H, ArH), 7.07 (d, 4 H, ArH); IR (CCl₄) 3320 cm⁻¹ (OH, NH).

erythro-5,6-Bis(4-hydroxyphenyl)-1-octylamine (33). Methyl ether 30 (1.77 g, 5.2 mmol) was cleaved (10 mL of a 1 M BBr₃ solution) to yield 0.98 g (60%) of an amorphous solid: ¹H NMR (400 MHz, acetone- d_6) δ 0.49 (t, 3 H, 8-H), 0.83-1.06 (m, 2 H, 3-H), 1.18-1.46 (m, 6 H, 2-, 4-, 7-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.60 (dt, J = 4.5, 10, 10 Hz; 1 H, 5-H), 2.96 (m, 2 H, 1-H), 6.78 (d, J = 8.5 Hz, 4 H, ArH), 7.04 (d, 2, J = 8.5 Hz, 4 H, ArH); MS (90 °C) m/z 313 (4, M⁺), 284 (3), 206 (6), 192 (6), 178 (100), 161 (55); exact mass calcd for C₂₀H₂₇NO₂ 313.20417, found 313.20537.

erythro-5,6-Bis(4-hydroxyphenyl)-N,N-bis(2-hydroxyethyl)-1-octylamine (34). Diethyl ether 31 (260 mg, 0.61 mmol) was cleaved with 0.2 mL of a 1 M BBr₃ solution in CH₂Cl₂ to afford 128 mg (53%) of the oily phenol after TLC separation (CH₂Cl₂/20% MeOH): ¹H NMR (250 MHz, acetone- d_6) δ 0.50 (t, 3 H, 8-H), 0.87–1.65 (m, 8 H, 2-, 3-, 4-, 7-H), 2.48 (dt, 1 H, 6-H), 2.65 (m, 1 H, 5-H), 2.79 (t, 2 H, 1-H), 3.04 (t, 4 H, NCH₂) 3.76 (t, 4 H, CH₂OH), 6.85 (d, 2, 4 H, ArH), 7.09 (d, 2, ArH); MS (170 °C) m/z 401 (1, M⁺), 370 (100), 340 (2), 294 (2), 266 (37), 236 (21), 204 (38), 157 (42); exact mass calcd for C₂₄H₃₅NO₄ 401.2566, found 401.2541.

erythro-5,6-Bis(4-hydroxyphenyl)-N-(2-hydroxyethyl)-1-octylamine (35). A solution of 67 mg (0.17 mmol) of methyl ether 32 was cleaved with 0.1 mL of a 1 M solution of BBr₃ to yield 34 mg (54%) of oily bisphenol 35: ¹H NMR (250 MHz, acetone- d_6) δ 0.5 (t, 3 H, 8-H), 0.92–1.13 (m, 2 H, 3-H), 1.23–1.80 (m, 3 H, 2-, 4-, 7-H), 2.47 (m, 1 H, 6-H), 2.70 (m, 1 H, 5-H), 2.87 (m, 2 H, 1-H), 3.14 (m, 2 H, 1-H), 3.84 (m, 2 H, CH₂O), 6.82 (2 d, 4 H, ArH), 7.10 (d, 2, 4 H, ArH).

erythro-5,6-Bis(4-hydroxyphenyl)-N,N-bis(2-chloroethyl)-1-octylamine Hydrochloride (36). A solution of 58 mg (0.14 mmol) of 34 in 5 mL of absolute dichloromethane was treated with 0.1 mL (1.42 mmol) of thionyl chloride and stirred for 3 h at room temperature. The solvent was removed under reduced pressure and the residue crystallized from ethyl acetate/diethyl ether to yield 52 mg (76%) of bischloride 36: mp 300-202 °C; ¹H NMR (300 MHz, acetone- d_6) δ 0.50 (t, J = 7.5 Hz, 3 H, 8-H), 0.90-1.04 (m, 2 H, 3-H)8 1.18-1.45 (m, 6 H, 2-, 4-, 7-H), 1.68 (cm, 2 H, 1-H), 2.46 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.65 (ddd, 1 H, 5-H), 3.51 (t, J = 6.5 Hz, 4 H, 1′H), 4.09 (t, J = 6.5 Hz, 4 H, CH₂Cl), 6.80 (2 d, J = 8.5 Hz, 4 H, ArH), 7.07 (2 d, J = 8.5 Hz, 4 H, ArH),8.28 (br s, 2 H, ArOH); MS (180 °C) m/z 439/437 (M⁺, Cl = 37/35), 388, 348, 332, 302 (21), 254, 240, 212 (8), 204 (12), 197 (84), 161 (41); exact mass calcd for C₂₄H₃₃NO₂³⁵Cl₂ 437.1888, found 437.1870.

erythro-5,6-Bis(4-hydroxyphenyl)-N-(2-chloroethyl)-1octylamine Hydrochloride (37). A solution of 25 mg (0.07 mmol) of amino alcohol 35 was chlorinated with 0.1 mL of thionyl chloride as described for 36 to yield 19 mg (75%) of chloride 37: mp 167 °C; ¹H NMR (250 MHz, acetone- d_6) δ 0.50 (t, 3 H, 8-H), 0.86–1.83 (m, 8 H, 2-, 3-, 4-, 7-H), 2.30 (m, 2 H, 1-H), 2.47 (m, 1 H, 6-H), 2.67 (m, 1 H, 5-H), 3.36 (t, 2 H, 1'-H), 4.04 (t, 2 H, CH₂Cl), 6.82 (2 d, 4 H, ArH), 7.09 (m, 4 H, ArH); MS (200 °C) m/z 340 (M⁺ – Cl), 326, 302, 300, 272, 270, 240, 222 (90), 178 (60), 135 (81); exact mass calcd for C₂₂H₃₀NO₂ 340.2276, found 340.2265.

N-Nitroso-N-(2-chloroethyl)-N'-[5,6-bis(hydroxyphenyl)octyl]urea (38). A solution of 30 mg (0.10 mmol) of amine 33 in 5 mL of dry pyridine was treated with 200 mg of N-nitrosoazide 40^{26-28} in absolute diethyl ether and stirred overnight. The solvent was removed under reduced pressure. Methanol was added repeatedly and evaporated. The residue was purified by TLC ($CH_2Cl_2/5\%$ MeOH) to afford 29 mg (68%) of oily 38: ¹H NMR (300 MHz, CDCl₃) δ 0.53 (t, J = 7.5 Hz, 3 H, 8-H), 0.86-1.05 (m, 2 H, 3-H), 1.19-1.51 (m, 6 H, 2-, 4-, 7-H), 2.43 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.55 (dt, J = 4.5, 10, 10 Hz;1 H, 5-H, 3.24 (m, 2 H, 1-H), 3.45 (t, J = 7 Hz, 2 H, NCH₂CH₂Cl),4.13 (t, J = 7 Hz, 2 H, NCH₂CH₂Cl), 4.71 (br s, 2 H, OH), 6.65 (br t, 1 H, NH), 6.78 (2 d, J = 8.5 Hz, 4 H, ArH), 7.01 (d, J =8.5 Hz, ArH); MS (280 °C) m/z 382 (M⁺ – NO – Cl) 339 (M⁺ – HON₂CH₂CH₂Cl), 311, 309, 284, 247, 204, 135, 107, 56, 36; negative FAB-MS m/z 419/417 (M⁺ - NO), 381, 339, 338, 312, 275, 211, 183; exact mass calcd for $C_{23}H_{30}N_2O_3$ 382.22564, found 382.22563; for C₂₁H₂₅NO₃ 339.18343, found 339.18288; for C₁₆H₂₂N₂O₂³⁷Cl 311.13403, found 311.13575.

erythro -5,6-Bis(4-methoxyphenyl)-N-(3-hydroxypropyl)-1-octylamine (41). A THF solution of 1.30 g (2.9 mmol) of amide 25 was reduced with 0.16 g (4.3 mmol) of LAH as described for 31 to afford 0.75 g (65%) of 41: mp 154 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 0.91 (m, 2 H, 3-H), 1.30 (m, 4 H, 4-, 7-H), 1.55 (m, 2 H, 2-H), 1.88 (m, 2 H, 2'-H), 2.42 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.54 (m, 1 H, 5-H), 2.62 (t, 2 H, 1-H), 2.95 (t, 2 H, 1'-H), 3.67 (t, 2 H, 3'-H), 3.80 (s, 6 H, OCH₃), 6.83 (2 d, J = 8.5 Hz, 4 H, ArH), 7.05 (2 d, J = 8.5 Hz, 4 H, ArH); positive FAB-MS m/z 400 (MH⁺).

N,N-Bis(2-chloroethyl)-N'-(erythro-5,6-bis(4-methoxyphenyl)-1-octyl)-N',O-propylenephosphoric Acid Ester Diamide (43). A solution of 194 mg (0.49 mmol) of N-(3hydroxypropyl)octylamine 41 and 164 mg (0.63 mmol) of N,Nbis(2-chloroethyl)phosphoric acid dichloride³¹ (42) in 15 mL of dry pyridine was stirred for 12 h under nitrogen. The solvent was removed under reduced pressure and the residue treated with

Hexestrol-Linked Cytotoxic Agents

methanol and again evaporated. The residue was taken up in 30 mL of dichloromethane, washed with water, dried (Na_2SO_4) , evaporated, and purified by TLC (dichloromethane/5% methanol) to afford 268 mg (94%) of oily 43: ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, 3 H, 8-H), 0.87 (m, 2 H, 3-H), 1.23–1.37 (m, 6 H, 2-, 4-, 7-H), 1.70-1.94 (m, 2 H, PNCH₂CH₂CH₂O), 2.44 (dt, 1 H, 6-H), 2.55 (m, 1 H, 5-H), 2.55-2.69 (m, 2 H, NCH₂), 2.91-3.09 (m, 2 H, NCH₂), 3.15–3.25 (m, 2 H, NCH₂), 3.31–3.42 (m, 2 H, NCH₂), 3.52 (m, 4 H, N(CH₂CH₂Cl)₂), 3.82 (s, 6 H, OCH₃), 4.09-4.36 (m, 2 H, POCH₂R), 6.86 (d, 4 H, ArH), 7.06 (2 d, 4 H, ArH); ³¹P NMR (24.3 MHz, CDCl₃) δ 13.50 (s), 13.87 (s); ¹³C NMR (75.5 MHz, CDCl₃) δ 12.19 (q, C-8), 25.05, 25.10 (t, C-3), 26.20, 26.26 (t, C-2), 27.17, 27.23 (t, C-7), 27.36, 27.43 (t, C-4), 34.17, 34.26 (t, (PNCH₂CH₂O), 42.31 (t, 2 CH₂Cl), 46.44 (t, NCH₂CH₂Cl), 47.98 (t, NCH₂CH₂Cl), 49.40 (t, C-1, PNCH₂(CH₂)₂O), 51.46, 51.60 (d, C-5), 53.67, 53.76 (d, C-6), 55.20 (q, oCH₃), 66.88, 66.97 (t, POCH₂), 113.63, 113.68 (d, C-11, 13, 17, 19), 129.05, 129.13 (d, C-10, 14, 16, 20), 136.36, 136.47 (s, C-9, 15), 157.85 (s, C-12, 18), 1250 cm⁻¹ (PO); MS (180 °C) m/z 584 (M⁺, Cl = 35), 549, 481, 435, 273, 259, 211, 149; exact mass calcd for C₂₉H₄₃N₂O₄Cl₂P 582.21808, found 582.21697.

N,N-Bis(2-chloroethyl)-N'-(erythro-5,6-bis(4-hydroxyphenyl)-1-octyl)-N',O-propylenephosphoric Acid Ester Diamide (44). A solution of 130 mg (0.22 mmol) of cyclophosphamide 43 in 10 mL of dry dichloromethane was treated with 1 mL of a 1 M BBr₃ solution as described for 34. After usual workup 121 mg (98%) of oily HEX-linked cyclophosphamide 44 was isolated: ¹H NMR (400 MHz, acetone- d_6) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 0.92 (m, 2 H, 3-H), 1.21–1.51 (m, 6 H, 2-, 4-, 7-H) 1.76-1.98 (m, 2 H, PNCH₂CH₂CH₂O), 2.48 (dt, 1 H, 6-H), 2.58 (m, 1 H, 5-H), 2.58–2.79 (m, 2 H, NCH₂), 2.97–3.13 (m, 2 H, NCH₂), 3.25-3.48 (m, 4 H, 2 NCH₂), 3.64 (t, 4 H, N(CH₂CH₂Cl)₂), 4.15-4.30 (m, 2 H, PNCH₂CH₂CH₂O), 6.80 (2 d, 4 H, ArH), 7.06 (2 d, 4 H, ArH), 8.47 (2 s, 2 H, ArOH); ³¹P NMR (162 MHz, acetone- d_6) δ 14.55 (s), 14.71 (s); ¹³C NMR (100.6 MHz, acetone- d_6) δ 12.54 (t, C-8), 25.82 (t, C-3), 26.91 (t, C-2), 28.00 (t, C-7, C-4), 35.09 (t, PNCH₂CH₂CH₂O), 42.91 (t, CH₂Cl), 47.27 (t, NCH₂CH₂Cl), 48.73 (t, NCH₂CH₂Cl), 50.00 (t, C-1, PNCH₂CH₂CH₂O), 52.18 (d, C-5), 54.36 (d, C-6), 68.14 (t, POCH₂), 115.82 (d, C-11, 13, 17, 19), 129.45 (C-10, 14, 16, 20), 136.04 (s, C-9, 15), 156.54 (s, C-12, 18); MS (250 °C) m/z 421, 385, 359, 273, 254, 239, 149, 135, 120, 107, 92, 70, 57, 41. Anal. (C₂₇H₃₉Cl₂N₂O₄P) C, H, N.

erythro-5,6-Bis[4-(tert-butyldimethylsiloxy)phenyl]octanoic Acid (45). A solution of 1.00 g (3.1 mmol) of acid 51, 2.06 g (13.7 mmol) dimethyl-tert-butylsilyl chloride, and 1.56 (22.9 mmol) of imidazole in 5 mL of dry DMF was stirred under nitrogen at room temperature. After 12 h 1 mL of methanol was added and stirring was continued for 1 h. The mixture was diluted with 100 mL of diethyl ether and extracted three times with 10 mL of water. The organic phase was dried and evaporated under reduced pressure and crystallized from diethyl ether/petroleum ether to afford 1.58 mg (93%) of acid 45: mp 105–106 °C, ¹H NMR (300 MHz, CDCl₃) δ 0.20 (s, 6 H, CH₃Si), 0.51 (t, J = 7 Hz, 3 H, 8-H), 0.97 (s, 18 H, tert-butyl-H), 1.16–1.46 (m, 6 H, 3-, 4-, 7-H), 1.96–2.16 (m, 2 H, 2-H), 2.41 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.54 (m, 1 H, 5-H), 6.75 (d, J = 8.5 Hz, 4 H, ArH), 6.96 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 1710 cm⁻¹ (CO).

erythro-5,6-Bis[4-(tert-butyldimethylsiloxy)phenyl]-1octanol (46). A mixture of 1.51 g (2.7 mmol) of acid 45 and 0.08 g (2.1 mmol) of LAH in 25 mL of absolute THF was stirred for 4 h. Workup was carried out as described for 31 to afford 1.27 g (86%) of alcohol 46: mp 84-86 °C; ¹H NMR (90 MHz, CDCl₃) δ 0.20 (s, 12 H, CH₃Si), 0.50 (t, J = 7 Hz, 3 H, 8-H), 1.00 (s, 18 H, tert-butyl-H), 1.10-1.62 (m, 8 H, 2-, 3-, 4-, 7-H), 2.56-2.69 (m, 2 H, 5, 6-H), 3.40 (t, J = 6 Hz, 2 H, 1-H), 6.77 (d, J = 8 Hz, 4 H, ArH), 6.94 (d, J = 8 Hz, 4, ArH).

erythro-5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-1octyl Acetate (47). A solution of 100 mg (0.18 mmol) of alcohol 46 in 3 mL of dry pyridine was acetylated with 0.3 mL (3.00 mmol) of acetic anhydride. Usual workup afforded 158 mg of crude acetate 47, which was directly desilylated to 52.

erythro -5,6-Bis[4-(tert-butyldimethylsiloxy)phenyl]-1octyl Chloroacetate (48). To a solution of 158 mg (0.29 mmol) of alcohol 46 in 10 mL of absolute pyridine and 10 mL of absolute diethyl ether was added dropwise a solution of 0.04 mL (0.44 mmol) of chloroacetic acid chloride in 10 mL of absolute diethyl ether. After stirring for 1 h the solvent was removed under reduced pressure and the residue was dissolved in diethyl ether. The organic phase was washed with an aqueous solution of ammonium chloride and water, dried, and evaporated. The oily product 48 was separated from the mixture by TLC, the polar fraction yielding 75 mg: ¹H NMR (60 MHz, CDCl₃) δ 0.2 (s, 12 H, CH₃Si), 0.52 (t, J = 7 Hz, 3 H, 8-H), 1.03 (s, 18 H, *tert*-butyl-H), 0.82–1.70 (m, 8 H, 2-, 3-, 4-, 7-H), 0.80 (d, J = 8 Hz, 4 H, ArH), 7.03 (d, J = 8 Hz, 4 H, ArH).

erythro-5,6-Bis[4-(tert-butyldimethylsiloxy)phenyl]-1octyl Mesylate (49). A solution of 134 mg (0.25 mmol) of alcohol 46 in 4 mL of pyridine was mesylated with 0.1 mL (1.24 mmol) of mesyl chloride by standard procedures to afford 120 mg (78%) of 49, which was directly desilylated.

erythro-5,6-Bis[4-(tert-butyldimethylsiloxy)phenyl]-1octyl Tosylate (50). A solution of 138 mg (0.25 mmol) of alcohol 46 in 4 mL of dry pyridine was tosylated with 255 mg (1.34 mmol) of tosyl chloride to yield 107 mg (60%) of crude product which was directly desilylated.

 $(5S^*, 6R^*)$ -5,6-Bis(4-hydroxyphenyl)octanoic Acid (51). Two grams (5.6 mmol) of dimethyl ether 2 was treated at -50 °C with 0.5 mL of BBr₃ (5.6 mmol) as described for 11 to afford 1.71 g (93%) of 51: mp 101 °C; ¹H NMR (400 MHz, CDCl₃/dioxane) δ 0.52 (t, J = 7 Hz, 3 H, 8-H), 1.18–1.45 (m, 6 H, 3-, 4-, 7-H), 2.07 (m, 2 H, 2-H), 2.42 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.57 (dt, J = 4, 10, 10 Hz, 1 H, 5-H), 6.74 (d, J = 8.5 Hz, 4 H, ArH), 7.00 (2 d, J = 8.5 Hz, 4 H, ArH); IR (KBr) 1700 cm⁻¹ (COOH); MS (140 °C) m/z 328 (6, M⁺), 193 (81), 175 (18), 165 (6), 147 (18), 135 (100); exact mass calcd for C₂₀H₂₄O₄ 328.16744, found 328.1674.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Acetate (52). Desilylation of acetate 47 (see 54) afforded 36 mg (60%) of bisphenol 52: mp 113–114 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7 Hz, 3 H, 8-H), 0.96 (m, 2 H, 3-H), 1.18–1.53 (m, 6 H, 2-, 4-, 7-H), 1.96 (s, 3 H, COCH₃), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.56 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.85 (m, 2 H, 1-H), 9.97 (br s, 2 H, OH), 6.80 (d, J = 8.5 Hz, 4 H, ArH), 7.01 (d, 2, J = 8.5 Hz, 4 H, ArH); IR (CH₂Cl₂) 3580 (OH), 1730 cm⁻¹ (CO); MS (130 °C) m/z 356 (2, M⁺), 221 (83), 179 (20), 161 (96), 149 (20), 135 (100). Anal. (C₂₂H₂₈O₄) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Chloroacetate (53). A solution of 75 mg (0.12 mmol) of chloroacetate 48 in 5 mL of THF (Teflon block) was treated with 100 mg of KF and ca. 30 mg of 18-crown-6 and stirred for 0.5 h. The product was purified by TLC and crystallized from diethyl ether/petroleum ether: yield 29 mg (61%) of phenol 53; mp 119–120 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7 Hz, 3 H, 8-H), 0.96 (m, 2 H, 3-H), 1.19–1.75 (m, 6-H, 2-, 4-, 7-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.55 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 4.86 (s, 2 H, COCH₂Cl), 4.95 (m, 2 H, 1-H), 4.78 (br s, 2 H, OH), 6.86 (d, J = 8 Hz, 4 H, ArH), 7.01 (d, J = 8 Hz, 4 H, ArH); MS (160 °C) m/z 392/390 (M⁺), 284, 257, 255, 228, 213, 185, 149, 135 (100), 129, 111, 97, 73, 69, 57, 55, 43, 41. Anal. (C₂₂H₂₇O₄Cl) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Mesylate (54). Crude mesylate 49 (107 mg, 0.15 mmol) was desilylated as described for 52 to yield 64 mg (89%) of oily bisphenol 54: ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7 Hz, 3 H, 8-H), 1.01 (m, 2 H, 3-H), 1.19–1.74 (m, 6 H, 2-, 4-, 7-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.53 (dt, J = 4.0, 10, 10 Hz, 1 H, 5-H), 2.87 (s, 3 H, OSO₂CH₃), 3.99 (m, 2 H, 1-H), 4.88 (br s, 2 H, OH), 6.79 (2 d, J = 8.5 Hz, 4 H, ArH), 7.02 (2 d, J = 8.5 Hz, 4 H, ArH); IR (acetone) 1265, 1180 cm⁻¹ (SO₃); MS (200 °C) m/z 294, 293, 257, 197, 161, 149, 135. Anal. (C₂₁H₂₈O₅S) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl Tosylate (55). The desilylation of 50 afforded 64 mg (89%) of oily bisphenol 55: ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 8-H), 0.91 (m, 2 H, 3-H), 1.14–1.52 (m, 6 H, 2-, 4-, 7-H), 2.40 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.45 (s, 3 H, CH₃), 2.49 (dt, J = 4.5, 10, 10 Hz, 1 H, 5 H), 3.79 (m, 2 H, 1-H), 4.92 (s, 2 H, OH), 6.79 (2 d, J = 8.5, 4 H, ArH), 6.98 (2 d, J = 8.5 Hz, 4 H, ArH); IR (acetone) 1265, 1180 cm⁻¹ (SO₃); MS (275 °C) m/z 468 (M⁺), 457, 431, 363, 333, 297, 267, 203, 172. Anal. (C₂₇H₃₂O₅S) C, H.

erythro-Benzyl 5,6-Bis[4-(benzyloxy)phenyl]octanoate (56). A solution of 3.80 g (12 mmol) of acid 51 in 50 mL of dry THF was treated with 5.5 g (49 mmol) of potassium *tert*-butoxide and 4.50 mL (38 mmol) of benzyl bromide. After 4 h at reflux the solution was diluted with 200 mL of diethyl ether, washed with water and diluted HCl, dried, and evaporated. Crystallization from diethyl ether/petroleum ether afforded 6.7 g (97%) of benzyl ester 56: mp 147-148 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, 3 H, 8-H), 1.18-1.46 (m, 6 H, 3-, 4-, 7-H), 2.11 (m, 2 H, 2-H), 2.45 (dt, 1 H, 6-H), 2.58 (m, 1 H, 5-H), 5.98 (s, 2 H, COOCH₂Ph), 5.03 (s, 4 H, ArOCH₂Ph), 6.92 (d, 4 H, ArH), 7.04 (2 d, 4 H, ArH), 7.22-7.45 (m, 15 H, phenyl-H), 1710 cm⁻¹ (CO).

Methyl erythro-5,6-Bis(4-hydroxyphenyl)octanoate (57). A solution of 1.00 g (3.1 mmol) acid 51 in 50 mL of diethyl ether was treated with a 0.5 M ethereal solution of diazomethane so that the yellow color of the solution persisted for 2 min. The solvent and excess diazomethane were removed under reduced pressure and the residue crystallized from dichloromethane to yield 0.99 g (95%) of ester 57: mp 109–111 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.54 (t, J = 7.5 Hz, 3 H, 8-H), 1.18–1.46 (m, 6 H, 3-, 4-, 7-H), 2.00–2.18 (m, 2 H, 2-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.57 (m, 1 H, 5-H), 3.55 (s, 3 H, OCH₃), 4.89, 4.93 (s, 1 H, ArOH), 6.78 (d, J = 8.5 Hz, 4 H, ArH), 7.00 (2 d, J = 8.5 Hz, 4 H, ArH); 11 (10), 293 (6), 279 (2), 207 (84), 175 (46), 147 (16), 135 (86), 133 (100). Anal. (C₂₁H₂₆O₄) C, H.

erythro-5,6-Bis[4-(benzyloxy)phenyl]-1-octanol (58). A solution of 1.82 g (3.04 mmol) of benzyl ester 57 in 20 mL of THF was reduced with 0.06 g (1.52 mmol) of LAH as described for 3 to give 1.49 g (99%) of alcohol 58: mp 123-124 °C (diethyl ether/petroleum ether); ¹H NMR (90 MHz, CDCl₃) δ 0.49 (t, 3 H, 8-H), 0.78-1.56 (m, 8 H, 2-, 3-, 4-, 7-H), 2.30-2.67 (m, 2 H, 5-, 6-H), 3.38 (t, J = 3 Hz, 2 H, 1-H), 5.0 (s, 4 H, ArCH₂Ph), 6.89 (d, J = 8 Hz, 4 H, ArH), 7.04 (d, J = 8 Hz, 4 H, ArH), 7.27-7.51 (m, 10 H, phenyl-H); MS (250 °C) m/z 494 (M⁺), 493, 492, 269, 225.

erythro-5,6-Bis[4-(benzyloxy)phenyl]-1-octyl Iodide (59). Alcohol 58 (1.75 g, 3.54 mmol) was reacted with 3.68 g (10.6 mmol) of dicyclohexylcarbodiimidium iodide²³ as described for 8 to yield 1.95 g (88%) of iodide 59: mp 119 °C (diethyl ether/petroleum ether); ¹H NMR (300 MHz, CDCl₃) δ 0.54 (t, 3 H, 8-H), 0.99 (m, 2 H, 3-H), 1.18–1.72 (m, 6 H, 2-, 4-, 7-H), 2.45 (dt, 1 H, 6-H), 2.56 (m, 1 H, 5-H), 2.94 (m, 2 H, 1-H), 5.05, 5.06 (each s, each 2 H, ArOCH₂), 6.94 (d, 4 H, ArH), 7.07 (2 d, 4 H, ArH), 7.32–7.47 (m, 10 H, phenyl-H).

erythro-5,6-Bis[4-(benzyloxy)phenyl]-1-octyl 2-Hydroxyethyl Ether (60). A solution of 0.2 mL (3.59 mmol) of ethylene glycol in 10 mL of dry THF was treated with 72 mg (1.79 mmol) of sodium hydride (60% in oil) and stirred for 0.5 h at 20 °C and then 370 mg (0.61 mmol) of iodide 59 was added. The product was crystallized from diethyl ether after usual workup to afford 262 mg (79%) of 60: mp 129–130 °C, ¹H NMR (400 MHz, CDCl₃) δ 0.54 (t, 3 H, 8-H), 0.96 (m, 2 H, 3-H), 1.19–1.47 (m, 6 H, 2-, 4-, 7-H), 2.46 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.58 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.24 (m, 2 H, 1-H), 3.40 (m, 2 H, ROCH₂CH₂OH), 3.63 (m, 2 H, CH₂OH), 5.04 (s, 2 H, ArOCH₂Ph), 6.93 (2 d, J = 8.5 Hz, 4 H, ArH), 7.06 (2 d, J = 8.5 Hz, 4 H, ArH), 7.31–7.48 (m, 10 H, phenyl-H). Anal. (C₃₆H₄₂O₄) C, H.

erythro-5,6-Bis[4-(benzyloxy)phenyl]-1-octyl Diethylene Glycol Monoether (61). From 370 mg (0.61 mmol) of iodide 59, 0.3 mL (3.16 mmol) of diethylene glycol, and 38 mg (1.58 mmol) of sodium hydride, 277 mg (78%) of 61 was prepared as described for 60: mp 102–103 °C (diethyl ether); ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, 3 H, 8-H), 0.95 (m, 2 H, 3-H), 1.18–1.49 (m, 6 H, 2-, 4-, 7-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.58 (dt, J = 4.5, 10,10 Hz, 1 H, 5-H), 3.22 (m, 2 H, 1-H), 3.45 (m, 2 H, OCH₂CH₂OR), 3.57 (m, 4 H, ROCH₂CH₂OCH₂CH₂OH), 3.67 (m, 2 H, CH₂OH), 5.06 (2 s, 4 H, ArOCH₂Ph), 6.92 (d, 4 H, ArH), 7.05 (2 d, 4 H, ArH), 7.31–7.46 (m, 10 H, phenyl-H). Anal. (C₃₈H₄₆O₈) C, H.

erythro-5,6-Bis[4-(benzyloxy)phenyl]-1-octyl Triethylene Glycol Monoether (62). From 370 mg (0.61 mmol) of iodide 59, 0.3 mL (2.25 mmol) of triethylene glycol, and 45 mg (1.12 mmol) of sodium hydride, 285 mg (74%) of 62 was prepared as described for 60: mp 79 °C (diethyl ether); ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7.5 Hz, 3 H, 8-H), 0.95 (m, 2 H, 3-H), 1.20–1.47 (m, 6 H, 2-, 4-, 7-H), 2.45 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.57 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.22 (m, 2 H, 1-H), 3.39–3.77 (m, 12 H, R(OCH₂CH₂)₃OH), 5.06 (2 s, 4 H, OCH₂Ph), 6.92 (2 d, J = 8.5 Hz, 4 H, ArH), 7.05 (2 d, J = 8.5 Hz, 4 H, ArH), 7.30–7.50 (m, 10 H, phenyl-H). Anal. (C₄₀H₅₀O₆) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl 2-Chloroethyl Ether (63). A solution of 55 mg (0.15 mmol) of alcohol 69 was chlorinated with 0.2 mL of thionyl chloride as described for 6 to yield after TLC purification (dichloromethane/2% methanol) 46 mg (80%) of chloride 63: mp 108 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.52 (t, 3 H, 8-H), 0.97 (m, 2 H, 3-H), 1.22–1.44 (m, 6 H, 2-, 4-, 7-H), 2.43 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.55 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.25 (m, 2 H, CH₂Cl), 3.53 (m, 4 H, CH₂OCH₂), 4.67 (s, 2 H, ArOH), 6.79 (2 d, 4 H, ArH), 7.00 (2 d, 4 H, ArH); MS (140 °C) m/z 376 (17, M⁺), 327 (9), 241 (39), 161 (97), 135 (88), 120 (8), 107 (100); exact mass calcd for C₂₂H₂₉O₃³⁵Cl 376.1805, found 376.1815. Anal. (C₂₂H₂₉O₃Cl) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl 2-(2-Chloroethoxy)ethyl Ether (64). Alcohol 70 (46 mg, 0.11 mmol) was chlorinated with 0.2 mL of thionyl chloride as described for 6 to yield 38 mg (79%) of oily chloride 64: ¹H NMR (300 MHz, CDCl₃) δ 0.52 (t, 3 H, 8-H), 0.95 (m, 2 H, 3-H), 1.20–1.44 (m, 6 H, 2-, 4-, 7-H), 2.42 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.54 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.23 (t, 2 H, CH₂Cl), 3.47 (m, 2 H, 1-H), 3.58 (m, 4 H, OCH₂CH₂OR), 3.69 (m, 2 H, OCH₂CH₂Cl), 4.81, 4.85 (s, 1 H, ArOH), 6.77 (2 d, 4 H, ArH), 7.00 (2 d, 4 H, ArH); MS (160 °C) m/z 422/420 (13/40, M⁺, Cl = 37/35), 327 (13), 285 (51), 161 (99), 135 (87). Anal. (C₂₄H₃₃O₄Cl) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl 2-[(2-Chloroethoxy)ethoxy]ethyl Ether (65). Alcohol 71 (63 mg, 0.14 mmol) was chlorinated with 0.2 mL of thionyl chloride as described for 6 to yield 51 mg (77%) of oily chloride 65: ¹H NMR (300 MHz, CDCl₃) δ 0.52 (t, 3 H, 8-H), 0.85–0.98 (m, 2 H, 3-H), 1.20–1.42 (m, 6 H, 2-, 4-, 7-H), 2.42 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.53 (dt, J = 4.5, 10, 10 Hz, 1 H, 5-H), 3.19 (t, 2 H, CH₂Cl), 3.40–3.77 (m, 12 H, RCH₂(OCH₂CH₂)₂OCH₂CH₂Cl), 5.01, 5.20 (each s, each 1 H, ArOH), 6.77 (2 d, 4 H, ArH), 7.00 (d, 4 H, ArH); MS (165 °C) m/z 464 (M⁺), 329, 161, 135, 107 (100); exact mass calcd for C₁₇H₂₆O₄Cl 329.1520, found 329.1515.

erythro-5.6-Bis(4-hydroxyphenyl)octanol (66). A solution of 135 mg (0.40 mmol) of ester 57 in 50 mL of toluene and 5 mL of dry diethyl ether was treated at -70 °C with 0.4 mL of diisobutylaluminum hydride (DIBAH) (1.2 M in toluene) for 2.5 h. An aqueous solution of citric acid was added and the mixture was repeatedly extracted with diethyl ether. The solution was dried and evaporated and the residue separated by TLC (dichloromethane/5% methanol) to afford 54 mg (0.24 mmol) of starting ester 57 and 63 mg (0.20 mmol) of aldehyde 66 (85% based on converted ester): mp 141 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.53 (t, J = 7 Hz, 3 H, 8-H), 1.20-1.37 (m, 6 H, 3-, 4-, 7-H), 2.17 (m, 7-H),2 H, 2-H), 2.44 (dt, 1 H, 6-H), 2.55 (m, 1 H, 5-H), 4.70 (s, 2 H, ArOH), 6.78 (2 d, J = 8.5 Hz, 4 H), 7.00 (2 d, J = 8.5 Hz, 4 H, ArH), 9.53 (t, J = 2 Hz, 1 H, 1-H); IR (KBr) 1715 cm⁻¹ (CO); MS (160 °C) m/z 312 (1, M⁺), 212 (3), 177 (41), 135 (98); exact mass calcd for C₂₀H₂₄O₃ 312.1725, found 312.1739.

erythro-6,7-Bis(4-hydroxyphenyl)-1-nonene (67). A solution of 457 mg (1.28 mmol) of triphenylmethylphosphonium bromide in 10 mL of dry THF was treated with 234 mg (1.92 mmol) of potassium tert-butoxide. A solution of 100 mg (0.32 mmol) of aldehyde 66 in 5 mL of THF was then added and the mixture was stirred for 2 h at 20 °C. The mixture was acidified with an aqueous solution of citric acid and extracted with diethyl ether. The ethereal solution was dried and evaporated and the residue purified by TLC to afford 51 mg (51%) of olefin which crystallized from diethyl ether: mp 162 °C; ¹H NMR (300 MHz, $\text{CDCl}_3/\text{acetone-}d_6) \delta 0.52 \text{ (t, } J = 7.3 \text{ Hz}, 3 \text{ H}, 9-\text{H}), 0.96-1.05 \text{ (m,}$ 2 H, 4-H), 1.18-1.43 (m, 4 H, 5-, 8-H), 1.70-1.89 (m, 2 H, 3-H), 2.42 (dt, 1 H, 7-H), 2.55 (dt, 1 H, 6-H), 4.75-4.84 (m, 2 H, 1-H), 5.58 (ddt, J = 6.5, 10, 17 Hz, 1 H, 2-H), 6.90 (d, J = 8.5 Hz, 4 H,ArH), 7.00 (2 d, J = 8.5 Hz, 4 H, ArH), 7.43, 7.44 (each s, each 1 H, OH); MS (80 °C) m/z 310 (0.7, M⁺), 212 (1), 175 (37), 135 (77), 119 (14), 107 (100); exact mass calcd for $C_{21}H_{26}O_2$ 310.19327, found 310.19304.

erythro-6,7-Bis(4-hydroxyphenyl)-1,2-epoxynonane (68). A solution of 32 mg (0.10 mmol) of olefin 67 and 21 mg (0.12 mmol) of *m*-chloroperbenzoic acid in dry diethyl ether was stirred for 5 h at 20 °C. The solution was reduced to one-third of the volume, filtered to remove *m*-chlorobenzoic acid, and evaporated and the residue was purified by TLC (dichloromethane/5% methanol) to yield 21 mg (62%) of epoxide 68: mp 50–51 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.52 (t, J = 7.5 Hz, 3 H, 9-H), 1.07–1.39 (m, 8 H, 3-, 4-, 5-, 7-H), 2.30 (m, 1 H, 1-H), 2.44 (dt, J = 3.5, 10, 10 Hz, 1 H, 7-H), 2.55 (dt, J = 4.5, 10, 10 Hz, 1 H, 6-H), 2.60 (m, 1 H, 1-H), 2.67 (m, 1 H, 2-H), 4.66 (br s, 2 H, ArOH), 6.78 (2 d, J = 8.5 Hz, 4 H, ArH), 7.01 (2 d, J = 8.5 Hz, 4 H, ArH); MS (250 °C) m/z 326 (M⁺), 297, 241, 227, 212, 191; exact mass calcd for C₂₁H₂₆O₃ 326.1882, found 326.1875.

erythro-5,6-Bis(4-hydroxyphenyl)-1-octyl 2-Hydroxyethyl Ether (69). A solution of 244 mg (0.45 mmol) of benzyl ether 60 in 100 mL of cyclohexane was hydrogenated for 4 h in the presence of ca. 50 mg of Pd/C. The catalyst was filtered off, the filtrate was evaporated, and the residue was crystallized from diethyl ether to yield 162 mg (100%) of bisphenol 69: mp 114-115 °C; ¹H NMR (300 MHz, acetone- d_6) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 0.97 (m, 2 H, 3-H), 1.21-1.40 (m, 6 H, 2-, 4-, 7-H), 2.46 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.61 (m, 1 H, 5-H), 3.61 (dt, 2 H, 1-H), 3.32 (m, 2 H, ROCH₂CH₂OH), 3.51 (m, 2 H, CH₂OH), 6.81 (2 d, J = 8.5 Hz, 4 H, ArH), 7.05 (2 d, J = 8.5 Hz, 4 H, ArH), 8.08 (s, 2 H, ArOH); MS (150 °C) m/z 358 (35, M⁺), 241 (16), 223 (61), 161 (100), 147 (8), 135 (87). Anal. C₂₂H₃₀O₄) C, H.

erythro-5,6-Bis(4-hydroxyphenyl)octyl Diethylene Glycol Monoether (70). Benzyl ether 61 (254 mg, 0.44 mmol) was hydrogenated as described for 69 to afford 158 mg (90%) of oily bisphenol 70: ¹H NMR (300 MHz, acetone- d_6) δ 0.51 (t, 3 H, 8-H), 0.97 (m, 2 H, 3-H), 1.21–1.42 (m, 6 H, 2-, 4-, 7-H), 2.47 (dt, J =3.5, 10, 10 Hz, 1 H, 6-H), 2.60 (dt, J = 5.0, 10, 10 Hz, 1 H, 5-H), 3.18 (dt, 2 H, 1-H), 3.38 (m, 2 H, OCH₂R), 3.47 (m, 4 H, OCH₂CH₂OCH₂CH₂OH), 3.58 (m, 2 H, CH₂OH), 6.79 (2 d, J =8.5 Hz, 4 H, ArH), 7.06 (2 d, J = 8.5 Hz, 4 H, ArH, 8.07 (s, 2 H, ArOH); MS (190 °C) m/z 402 (5, M⁺), 345 (8), 267 (17), 207 (8), 161 (100); exact mass calcd for C₂₄H₃₄O₅ 402.2406, found 402.2385.

erythro-5,6-Bis(4-hydroxyphenyl)-1-triethylene Glycol Monooctyl Ether (71). Benzyl ether 62 (268 mg, 0.43 mmol) was hydrogenated as described for **69** to yield 173 mg (91%) of oily bisphenol **71**: ¹H NMR (300 MHz, acetone- d_6) δ 0.51 (t, J = 7.5 Hz, 3 H, 8-H), 0.98 (m, 2 H, 3-H), 1.20–1.42 (m, 6 H, 2-, 4-, 7-H), 2.47 (dt, J = 3.5, 10, 10 Hz, 1 H, 6-H), 2.60 (dt, J = 5, 10, 10 Hz, 1 H, 5-H), 3.18 (dt, 2 H, 1-H), 3.36–3.63 (m, 12 H, R(OCH₂CH₂)₃OH), 6.81 (2 d, J = 8.5 Hz, 4 H, ArH), 7.07 (2 d, J = 8.5 Hz, 4 H, ArH), 8.08 (s, 2 H, ArOH); MS (270 °C) m/z 447 (MH⁺), 329, 311, 161, 151, 135; exact mass calcd for C₂₈H₃₉O₆ 447.27464, found 447.27411.

Registry No. (±)-erythro-1, 120578-46-3; (±)-threo-1, 120579-13-7; (\pm) -2, 120578-47-4; (\pm) -3, 120608-65-3; (\pm) -4, 120578-48-5; (\pm) -5, 120578-49-6; (\pm) -6, 120608-66-4; (\pm) -8, $120578-50-9; (\pm)-9, 120578-51-0; (\pm)-10, 120578-52-1; (\pm)-threo-10,$ $120579-15-9; (\pm)-11, 120578-53-2; (\pm)-12, 120578-54-3; (\pm)-13,$ 120578-55-4; (\pm) -14, 120578-56-5; (\pm) -15, 120578-57-6; (\pm) -16, $120578-58-7; (\pm)-17, 120578-59-8; (\pm)-18, 120578-60-1; (\pm)-19,$ $120578-61-2; (\pm)-20, 120578-62-3; (\pm)-21, 120578-63-4; (\pm)-22,$ 120578-64-5; (\pm) -23, 120578-65-6; (\pm) -24, 120578-66-7; (\pm) -25, 120578-67-8; (\pm) -26, 120578-68-9; (\pm) -27, 120578-69-0; (\pm) -28, 120578-70-3; (\pm) -29, 120578-71-4; (\pm) -30, 120578-72-5; (\pm) -31, $120578-73-6; (\pm)-32, 120578-74-7; (\pm)-33, 120578-75-8; (\pm)-34,$ 120578-76-9; (±)-35, 120578-77-0; (±)-36, 120579-12-6; (±)-36·HCl, 120578-78-1; (±)-37, 120579-11-5; (±)-37·HCl, 120578-79-2; (±)-38, 120578-80-5; 40, 60784-40-9; (±)-41, 120578-81-6; 42, 127-88-8; (\pm) -43, 120578-82-7; (\pm) -44, 120578-83-8; (\pm) -45, 120578-84-9; (\pm) -46, 120578-85-0; (\pm) -47, 120578-86-1; (\pm) -48, 120578-87-2; (\pm) -49, 120578-88-3; (\pm) -50, 120578-89-4; (\pm) -51, 120578-90-7; (\pm) -52, 120578-91-8; (\pm) -53, 120578-92-9; (\pm) -54, 120578-93-0; (±)-55, 120578-94-1; (±)-56, 120578-95-2; (±)-57, 120578-96-3; (\pm) -58, 120578-97-4; (\pm) -59, 120578-98-5; (\pm) -60, 120578-99-6; (±)-61, 120579-00-2; (±)-62, 120579-01-3; (±)-63, 120579-02-4; (\pm) -64, 120579-03-5; (\pm) -65, 120579-04-6; (\pm) -66, 120579-05-7; (\pm) -67, 120579-06-8; 68, 120579-07-9; (\pm) -69, 120579-08-0; (\pm) -70, 120579-09-1; (\pm) -71, 120579-10-4; 4-MeOC₆H₄C(Et)=C(n-C₄H₉)C₆H₄OMe₄, 120579-14-8; H₂N(CH₂)₂CO₂Et HCl, 4244-84-2; (C₆H₅)₃P⁺Me Br⁻, 1779-49-3; diethanolamine, 111-42-2.

Synthesis and Biological Evaluation of Certain 3- β -D-Ribofuranosyl-1,2,4-triazolo[4,3-*b*]pyridazines Related to Formycin Prepared via Ring Closure of Pyridazine Precursors

Yonghan Kang, Steven B. Larson, Roland K. Robins, and Ganapathi R. Revankar*

ICN Nucleic Acid Research Institute, 3300 Hyland Avenue, Costa Mesa, California 92626. Received September 6, 1988

All three amino-substituted $3-\beta$ -D-ribofuranosyl-1,2,4-triazolo[4,3-b]pyridazines (5, 19, and 20) structurally related to formycin A were prepared and tested for their antitumor and antiviral activity in cell culture. Dehydrative coupling of 4-amino-5-chloro-3-hydrazinopyridazine (7) with 3,4,6-tri-O-benzoyl-2,5-anhydro-D-allonic acid (6) in the presence of DCC and subsequent thermal ring closure of the reaction product (8) provided 8-amino-7-chloro-3-(2,3,5-tri-Obenzoyl- β -D-ribofuranosyl)-1,2,4-triazolo[4,3-b]pyridazine (9). Dehalogenation of 9, followed by debenzoylation, gave the formycin congener 8-amino-3- β -D-ribofuranosyl-1,2,4-triazolo[4,3-b]pyridazine (5). Similar condensation of 5-amino-4-chloro-3-hydrazinopyridazine (13) with 6 and dehalogenation of the cyclized product (16), followed by debenzoylation, gave the isomeric 7-amino-3- β -D-ribofuranosyl-1,2,4-triazolo[4,3-b]pyridazine (19). DCC-mediated coupling of 6 with 6-chloro-3-hydrazinopyridazine (12), followed by ammonolysis of the cyclized product (21) with liquid NH₃, provided a convenient route to 6-amino-3- β -D-ribofuranosyl-1,2,4-triazolo[4,3-b]pyridazine (20). The structural assignment of 5 was made by single-crystal X-ray diffraction analysis. Compounds 5, 19, 20, and certain deprotected nucleoside intermediates were evaluated against L1210, WI-L2, and CCRF-CEM tumor cell lines, as well as against DNA and RNA viruses in culture. These compounds did not exhibit any significant antitumor or antiviral activity in vitro.

Since the isolation^{1,2} and structural elucidation^{3,4} of the naturally occurring C-nucleoside antibiotic formycin A

 $(7\text{-amino-}3\text{-}\beta\text{-}D\text{-}ribofuranosyl-}1H\text{-}pyrazolo[4,3-d]pyrimidine, 1), several reports have appeared in the literature describing its diverse biological properties.⁵⁻⁷ Formycin$

Hori, M.; Ito, E.; Takita, T.; Umezawa, H. J. Antibiot., Ser. A 1964, 17, 96.

⁽²⁾ Koyama, G.; Umezawa, H. J. Antibiot., Ser. A 1965, 18, 175.

⁽³⁾ Robins, R. K.; Townsend, L. B.; Cassidy, F. C.; Gerster, J. F.; Lewis, A. F.; Miller, R. L. J. Heterocycl. Chem. 1966, 3, 110.

⁽⁴⁾ Koyama, G.; Maeda, K.; Umezawa, H.; Iitake, Y. Tetrahedron Lett. 1966, 597.

⁽⁵⁾ Suhadolnik, R. J. Nucleoside Antibiotics; Wiley-Interscience: New York 1970, pp 354–389.